Derivation Web · source_39bad39e83f34efa

source · application/json

source_39bad39e83f34efa

sha256 e3e50456e5594a5881fc84016360be7856c47c828d40b5383a7a7197b97d4fa8

by researka:v2 · 2026-07-20 19:14:40.275590+04:00

{"publication_id": "bb8686c3-28f9-4609-95f1-70d7581bf992", "traces": [{"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "Evidence-honesty note: 33/36 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This paper synthesizes evidence on pcsk9 inhibitors effects across 36 included source papers and 1548 high-confidence extracted claims. The evidence profile contains 3 direct clinical sources, 33 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base. Positive study-level signals are summarized in the cardiometabolic and longevity outcome classes; null signals are summarized in the safety and comorbidity, mortality and survival, and muscle function outcome classes; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the contextual adjacent evidence, safety, and skeletal, fracture, and bone outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.", "claim_id": "claim_1"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "Evidence-honesty note: 33/36 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.", "claim_id": "claim_2"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "This paper synthesizes evidence on pcsk9 inhibitors effects across 36 included source papers and 1548 high-confidence extracted claims.", "claim_id": "claim_3"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "The evidence profile contains 3 direct clinical sources, 33 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base.", "claim_id": "claim_4"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "Positive study-level signals are summarized in the cardiometabolic and longevity outcome classes; null signals are summarized in the safety and comorbidity, mortality and survival, and muscle function outcome classes; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the contextual adjacent evidence, safety, and skeletal, fracture, and bone outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.", "claim_id": "claim_5"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "The conclusion is that pcsk9 inhibitors effects remains a bounded evidence case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.", "claim_id": "claim_6"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.", "claim_id": "claim_7"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "This synthesis evaluates evidence on pcsk9 inhibitors effects across 36 included source papers and 1548 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.", "claim_id": "claim_8"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "The corpus contains 3 direct clinical sources, 33 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.", "claim_id": "claim_9"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.", "claim_id": "claim_10"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.", "claim_id": "claim_11"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.", "claim_id": "claim_12"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.", "claim_id": "claim_13"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.", "claim_id": "claim_14"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.", "claim_id": "claim_15"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "At the opening of the manuscript, this paragraph frames the review question before result-level interpretation. The recommendation-boundary safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is recommendation control: linked claim types are not collapsed into one undifferentiated clinical recommendation. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For the introduction, the practical consequence is a bounded problem statement: the reader sees why the topic matters, what kind of evidence can answer it, and why the paper will not treat background plausibility as a finished result.", "claim_id": "claim_16"}, {"candidate_sources": [], "citation_support": [{"cited_as": "Chen 2026", "directness": "direct", "doi": "10.1136/bmjopen-2025-112947", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "The background evidence for pcsk9 inhibitors effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Karatasakis 2017 [bundle:31], Chen 2026 [bundle:15], Gong 2025 [bundle:26] are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.", "excerpt": "INTRODUCTION: The 'strike early and strike strong' lipid-lowering strategy emphasises rapid reduction of low-density lipoprotein cholesterol (LDL-C) in patients with acute coronary syndrome (ACS). Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are increasingly used alongside statins to achieve guideline-recommended LDL-C targets after ACS. However, despite substantial LDL-C reductions with early PCSK9i initiation, their effects on non-culprit coronary atherosclerotic plaques remain unclear. This study aims to assess the impact of early intensive LDL-C lowering with PCSK9i added to moderate-intensity statin therapy on optical coherence tomography (OCT)-derived plaque characteristics in non-culprit coronary lesions in patients with ACS. METHODS AND ANALYSIS: In this prospective, multicentre, open-label trial, 212 patients with ACS will be randomised 1:1 to an early intensified lipid-lowering strategy (PCSK9i added to moderate-intensity statin) or guideline-directed medical therapy for 6 months. Serial OCT imaging of non-culprit coronary arteries with 20-70% stenosis will be performed at baseline and 6 months.", "population": "not extracted", "quote": "The primary endpoint will be analysed using analysis of covariance, adjusting for treatment group, baseline LDL-C stratification (≥1.8 vs <1.8 mmol/L), and baseline minimum FCT. 1 Because non-culprit plaques are prone to rupture and thrombosis, patients with ACS remain at elevated risk of recurrent cardiovascular events, especially during the first 30 to 90 days after discharge.", "source_id": "source_15", "study": "PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial", "support_kind": "bundle_reference", "url": "https://doi.org/10.1136/bmjopen-2025-112947"}, {"cited_as": "Gong 2025", "directness": "direct", "doi": "10.1186/s13063-024-08709-2", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "The background evidence for pcsk9 inhibitors effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Karatasakis 2017 [bundle:31], Chen 2026 [bundle:15], Gong 2025 [bundle:26] are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.", "excerpt": "BACKGROUND: Early neurological deterioration (END) is a critical determinant influencing the short-term prognosis of acute ischemic stroke (AIS) patients and is associated with increased mortality rates among hospitalized individuals. AIS frequently coexists with coronary heart disease (CHD), complicating treatment and leading to more severe symptoms and worse outcomes. Shared risk factors between CHD and AIS, especially elevated low-density lipoprotein cholesterol (LDL-C), contribute to atherosclerosis and inflammation, which worsen brain tissue damage. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer a promising treatment option. They effectively lower LDL-C levels and may help reduce END in AIS patients with CHD. This study aims to evaluate how effective PCSK9 inhibitors are in reducing END among this high-risk group and to provide new insights for treatment strategies. METHODS: This is a prospective, randomized, parallel-group, blinded-endpoint, single-center clinical study.", "population": "not extracted", "quote": "3.Inability to control severe hypertension (systolic blood pressure persistently ≥180 mmHg or diastolic blood pressure ≥110 mmHg after active treatment), severe infections (meeting criteria such as elevated body temperature ≥38°C, signs of shock, infection-related consciousness impairment, respiratory failure, and blood gas analysis PO 2 <60 mmH 2 O), or abnormal liver function (ALT > 100 IU/L or AST > 80 IU/L), renal dysfunction (glomerular filtration rate < 30 ml/min), or patients with bleeding tendencies in the blood system (platelets < 60×10 9 /L or APTT > 60 seconds or INR > 3). Secondary objectives include evaluating changes in daily living abilities, recurrence rates of cardiovascular and cerebrovascular events within 90 days, alterations in blood biochemical indices/markers, and variations in inflammatory factors between the two patient groups after treatment.", "source_id": "source_26", "study": "Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of coronary heart disease: a study protocol for a randomized controlled trial in Dalian, China", "support_kind": "bundle_reference", "url": "https://doi.org/10.1186/s13063-024-08709-2"}, {"cited_as": "Karatasakis 2017", "directness": "direct", "doi": "10.1161/JAHA.117.006910", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "The background evidence for pcsk9 inhibitors effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Karatasakis 2017 [bundle:31], Chen 2026 [bundle:15], Gong 2025 [bundle:26] are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.", "excerpt": "BACKGROUND: We sought to examine the efficacy and safety of 2 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors: alirocumab and evolocumab. METHODS AND RESULTS: We performed a systematic review and meta-analysis of randomized controlled trials comparing treatment with and without PCSK9 inhibitors; 35 randomized controlled trials comprising 45 539 patients (mean follow-up: 85.5 weeks) were included. Mean age was 61.0±2.8 years, and mean baseline low-density lipoprotein cholesterol was 106±22 mg/dL. Compared with no PCSK9 inhibitor therapy, treatment with a PCSK9 inhibitor was associated with a lower rate of myocardial infarction (2.3% versus 3.6%; odds ratio [OR]: 0.72 [95% confidence interval (CI), 0.64-0.81]; P <0.001), stroke (1.0% versus 1.4%; OR: 0.80 [95% CI, 0.67-0.96]; P =0.02), and coronary revascularization (4.2% versus 5.8%; OR: 0.78 [95% CI, 0.71-0.86]; P <0.001). Overall, no significant change was observed in all-cause mortality (OR: 0.71 [95% CI, 0.47-1.09]; P =0.12) or cardiovascular mortality (OR: 1.01 [95% CI, 0.85-1.19]; P =0.95).", "population": "not extracted", "quote": "We performed a systematic review and meta‐analysis of randomized controlled trials comparing treatment with and without PCSK9 inhibitors; 35 randomized controlled trials comprising 45 539 patients (mean follow‐up: 85.5 weeks) were included. Compared with no PCSK9 inhibitor therapy, treatment with a PCSK9 inhibitor was associated with a lower rate of myocardial infarction (2.3% versus 3.6%; odds ratio [OR]: 0.72 [95% confidence interval (CI), 0.64-0.81]; P <0.001), stroke (1.0% versus 1.4%; OR: 0.80 [95% CI, 0.67-0.96]; P =0.02), and coronary revascularization (4.2% versus 5.8%; OR: 0.78 [95% CI, 0.71-0.86]; P <0.001).", "source_id": "source_31", "study": "Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials", "support_kind": "bundle_reference", "url": "https://doi.org/10.1161/JAHA.117.006910"}], "claim": "The background evidence for pcsk9 inhibitors effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Karatasakis 2017 [bundle:31], Chen 2026 [bundle:15], Gong 2025 [bundle:26] are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.", "claim_id": "claim_17"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.", "claim_id": "claim_18"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "Across the retained sources, positive signals cluster around the cardiometabolic, contextual adjacent evidence and safety outcome classes; null signals around the safety and comorbidity, cardiometabolic, muscle function outcome classes; and negative or adverse signals around the cardiometabolic outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.", "claim_id": "claim_19"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.", "claim_id": "claim_20"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.", "claim_id": "claim_21"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.", "claim_id": "claim_22"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.", "claim_id": "claim_23"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.", "claim_id": "claim_24"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, longevity, mortality and survival, muscle function, safety, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.", "claim_id": "claim_25"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.", "claim_id": "claim_26"}, {"candidate_sources": [], "citation_support": [{"cited_as": "Hosseini 2024", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.1186/s12872-024-04057-w"}, {"cited_as": "Hollstein 2021", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "bundle_reference", "url": "https://doi.org/10.1007/s40256-020-00411-3"}, {"cited_as": "Imran 2023", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.1371/journal.pone.0295359"}, {"cited_as": "Scicali 2021", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "bundle_reference", "url": "https://doi.org/10.1007/s00592-021-01703-z"}, {"cited_as": "Rehues 2023", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "bundle_reference", "url": "https://doi.org/10.3390/ijms24032319"}, {"cited_as": "Cao 2025", "directness": "review", "doi": "10.3389/fcvm.2025.1612095", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Few percutaneous coronary intervention (PCI) patients achieve low-density lipoprotein cholesterol (LDL-C) targets with statins alone. While proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors effectively diminish LDL-C levels, their combined use with statins for reducing major adverse cardiovascular events (MACE) and improving lipid profiles post-PCI requires further validation. This study seeks to appraise the therapeutic impact of PCSK9 inhibitors combined with statins on MACE and blood lipids in patients following PCI. METHODS: Randomized controlled trials (RCTs) and cohort studies as of February 2025 in the PubMed, Embase, Cochrane Library, and Web of Science databases were identified. Regarding the risk of bias evaluation, Cochrane ROB 2.0 was employed for RCTs. Moreover, cohort studies were appraised by means of the Newcastle-Ottawa Scale. In terms of heterogeneity, it was appraised by means of the I 2 statistics. The relative risk (RR) and 95% confidence interval (CI) for dichotomous variables, along with the weighted mean difference (WMD), standardized mean difference (SMD), and their respective 95% CIs for continuous variables.", "population": "not extracted", "quote": "The relative risk (RR) and 95% confidence interval (CI) for dichotomous variables, along with the weighted mean difference (WMD), standardized mean difference (SMD), and their respective 95% CIs for continuous variables. The meta-analysis revealed that, against the statin group, the combination therapy group displayed a notable decline in MACE incidence (RR: 0.61; 95% CI: 0.50-0.75; p < 0.001; I 2 = 0.0%).", "source_id": "source_6", "study": "Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in patients after percutaneous coronary intervention: a systematic review and meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.3389/fcvm.2025.1612095"}, {"cited_as": "Liu 2024", "directness": "review", "doi": "10.3389/fcvm.2024.1454918", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: In recent years, the position of PCSK9 inhibitors as adjuvant therapy to statins in guidelines has further improved. However, there remained a dearth of direct comparative studies among different PCSK9 inhibitors. Therefore, this study aimed to conduct a network meta-analysis to evaluate the efficacy and safety of different PCSK9 inhibitors combined with statins. METHODS: A comprehensive literature search was conducted from the study's inception to 12 November 2023, encompassing multiple online databases including PubMed, Embase, Cochrane Central, Web of Science, and ClinicalTrials.gov to obtain relevant randomized controlled trials. Frequentist network meta-analysis was employed to compare the efficacy and safety of different PCSK9 inhibitors. The efficacy endpoints were low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and lipoprotein (a) (Lp(a)). The safety endpoints were any adverse events (AE), severe adverse events (SAE), AE leading to treatment discontinuation, and injection-site reaction. RESULTS: Compared with placebo and ezetimibe, all PCSK9 inhibitors demonstrated significant reductions in LDL-C levels.", "population": "not extracted", "quote": "Notably, evolocumab exhibited the most pronounced effect with a treatment difference of -63.67% (-68.47% to -58.87%) compared with placebo. Compared with placebo, it can reduce LDL-C levels by approximately 57%-65%, maintain long-term treatment efficacy, and exhibit strong lipid-lowering abilities for ApoB and Lp(a) ( 25 - 27 ).", "source_id": "source_7", "study": "The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.3389/fcvm.2024.1454918"}, {"cited_as": "Jing 2025", "directness": "indirect", "doi": "10.1038/s41598-025-26495-y", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "PROMIS effectively assesses patient health, but its use in evaluating the quality of life in acute coronary syndrome (ACS) patients on PCSK9 inhibitors (PCSK9i) remains unexplored. This study examined the impact of PCSK9i on quality of life in ACS patients, comparing PCSK9i plus statin versus statin-only therapy using PROMIS-10, and analyzed the association between PROMIS scores and major adverse cardiovascular events (MACE). The EMSIACS trial is a prospective, randomized, open-label, parallel-group, multicenter study registered at ClinicalTrials.gov (NCT04100434). This paper presents the exploratory outcomes of this trial. From September 2020 to March 2022, a total of 500 ACS patients were enrolled. Patients were randomly assigned in a 1:1 ratio to receive Evolocumab plus statin therapy or statin-only therapy. The quality of life was assessed using PROMIS 10 at baseline, week 12, and week 48. PROMIS 10 includes two summary scores: Global Physical Health (GPH, including physical health, physical function, fatigue and pain intensity) and Global Mental Health (GMH, including overall quality of life, mental health, satisfaction with social activities, and emotional problems).", "population": "not extracted", "quote": "At week 12, Evolocumab significantly improved Global Physical Health (GPH) ( P < 0.001) and Global Mental Health (GMH) scores ( P < 0.001), particularly in pain intensity, mental health, and social activity satisfaction ( P < 0.001). By week 48, both groups improved significantly from baseline, with no significant differences between them(GPH: P = 0.120; GMH: P = 0.105).", "source_id": "source_8", "study": "Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of the EMSIACS trial", "support_kind": "bundle_reference", "url": "https://doi.org/10.1038/s41598-025-26495-y"}, {"cited_as": "Raone 2025", "directness": "review", "doi": "10.1007/s40256-025-00778-1", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Residual cardiovascular risk remains substantial in patients with atherosclerotic cardiovascular disease (ASCVD) despite high-intensity statin therapy. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), including monoclonal antibodies and small-interfering RNA agents, offer additional risk reduction, yet comparative evidence across individual regimens remains limited. METHODS AND RESULTS: We conducted a systematic review and network meta-analysis of randomized controlled trials evaluating approved PCSK9i dosages in patients with ASCVD. The primary outcome was major adverse cardiovascular events (MACE); the secondary outcomes included myocardial infarction, stroke, coronary revascularization, cardiovascular mortality, and all-cause death. A total of eight trials involving 49,847 patients were included. Evolocumab (140 mg every 2 weeks or 420 mg monthly) and alirocumab 150 mg every 2 weeks significantly reduced MACE compared with placebo (risk ratios (RR): 0.78, 95% confidence intervals (CI): 0.66-0.93 and RR: 0.47, 95% CI 0.25-0.86, respectively). Evolocumab was also associated with reductions in myocardial infarction, stroke, and revascularization.", "population": "not extracted", "quote": "Evolocumab (140 mg every 2 weeks or 420 mg monthly) and alirocumab 150 mg every 2 weeks significantly reduced MACE compared with placebo (risk ratios (RR): 0.78, 95% confidence intervals (CI): 0.66-0.93 and RR: 0.47, 95% CI 0.25-0.86, respectively). Alirocumab 150 mg demonstrated the most pronounced effect on revascularization and was superior to both evolocumab and the lower alirocumab dose in this outcome.", "source_id": "source_9", "study": "Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.1007/s40256-025-00778-1"}, {"cited_as": "Song 2024", "directness": "review", "doi": "10.1097/MD.0000000000038360", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: The effect of proprotein convertase subtilisin kexin type (PCSK9) inhibitors on blood lipids and major adverse cardiovascular events (MACEs) is still controversial for acute coronary syndrome (ACS) patients. This study aimed to evaluate the efficacy and safety of PCSK9 inhibitors for ACS patients. METHODS: We searched the following databases until March 2023: PubMed, Embase, Cochrane, Web of Science, CNKI, Chongqing VIP Database and Wan Fang Database. Finally, all randomized controlled trials, retrospective studies and prospective studies were included in the analysis. RESULTS: A total of 20 studies involving 48,621 patients were included in this meta-analysis. The results demonstrated that PCSK9 inhibitors group was more beneficial for ACS patients compared to control group (receiving statins alone or placebo). The meta-analysis showed: there was no significant difference in high density lipoprotein cholesterol between PCSK9 inhibitors group and control group (standard mean difference = 0.17, 95% confidence interval [CI]: -0.02 to 0.36, P = .", "population": "not extracted", "quote": "The meta-analysis showed: there was no significant difference in high density lipoprotein cholesterol between PCSK9 inhibitors group and control group (standard mean difference = 0.17, 95% confidence interval [CI]: -0.02 to 0.36, P = .08), while the level of low density lipoprotein cholesterol in PCSK9 inhibitors group was lower than that in control group (standard mean difference = -2.32, 95% CI: -2.81 to -1.83, P < .00001). Compared with the control group, the PCSK9 inhibitors group also decreased the levels of total cholesterol and triglycerides (mean difference = -1.24, 95% CI: -1.40 to -1.09, P < .00001, mean difference = -0.36, 95% CI: -0.56 to -0.16, P = .0004).", "source_id": "source_10", "study": "Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary syndrome: A systematic review and meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.1097/MD.0000000000038360"}, {"cited_as": "Xiao 2024", "directness": "review", "doi": "10.3390/medicina60101646", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Background and Objectives : The proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab are recently developed promising drugs used for treatment of familial hypercholesterolemia (FH). This systematic review and meta-analysis aimed to thoroughly evaluate the efficacy and safety of evolocumab and alirocumab among pediatric patients with FH. Materials and Methods : A comprehensive search was conducted in PubMed, Embase, CENTRAL (Cochrane Central Register of Controlled Trials), and ClinicalTrials.gov from inception through July 2024 to identify primary interventional studies among pediatric patients with FH. Meta-analyses were performed if appropriate. Statistics were analyzed using Review Manager version 5.4 and Stata version 16.0. Results : Fourteen articles reporting nine unique studies were included. There were three randomized controlled trials (RCTs) assessing evolocumab or alirocumab involving a total of 320 pediatric patients, one cross-over trial and five single-arm or observational studies.", "population": "not extracted", "quote": "Pooled results showed significant efficacy of evolocumab/alirocumab in reducing low-density lipoprotein cholesterol (LDL-C) (weighted mean difference [WMD]: -37.92%, 95% confidence interval [CI]: -43.06% to -32.78%; I 2 = 0.0%, p = 0.60), apolipoprotein B (WMD: -33.67%, 95% CI: -38.12% to -29.22%; I 2 = 0.0%, p = 0.71), and also lipoprotein(a) (WMD: -16.94%, 95% CI: -26.20% to -7.69%; I 2 = 0.0%, p = 0.71) among pediatric patients with FH. Patients with concentrations of LDL-C of more than 190 mg/dL) and no FH mutations had a six times higher risk of coronary artery disease compared with people with concentrations of LDL-C of less than 130 mg/dL and no mutations.", "source_id": "source_11", "study": "Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.3390/medicina60101646"}, {"cited_as": "Choi 2023", "directness": "review", "doi": "10.1155/2023/7362551", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Alirocumab and evolocumab, as protein convertase subtilisin kexin type 9 (PCSK9) inhibitors, have been reported to reduce cardiovascular risk. This meta-analysis is aimed at updating the safety data of PCSK9 inhibitors. METHODS: We assessed the relative risk for all treatment-related adverse events, serious adverse events, diabetes-related adverse events, and neurocognitive and neurologic adverse events with PCSK9 inhibitors compared to controls (placebo or ezetimibe). In addition, we conducted a meta-analysis to quantitatively integrate and estimate the adverse event rates in long-term studies. RESULTS: There were no significant differences between PCSK9 inhibitors and controls in the relative risk analysis. In a subgroup analysis of each PCSK9 inhibitor, alirocumab treatment significantly reduced the risk of serious adverse events compared to control treatment (risk ratio (RR) = 0.937; 95% confidence interval (CI), 0.896-0.980), but no significant difference was observed with evolocumab treatment (RR = 1.003; 95% CI, 0.963-1.054).", "population": "not extracted", "quote": "In a subgroup analysis of each PCSK9 inhibitor, alirocumab treatment significantly reduced the risk of serious adverse events compared to control treatment (risk ratio (RR) = 0.937; 95% confidence interval (CI), 0.896-0.980), but no significant difference was observed with evolocumab treatment (RR = 1.003; 95% CI, 0.963-1.054). Moreover, alirocumab treatment afforded a significant reduction in the risk of diabetes-related adverse events compared to control treatment (RR = 0.9137; 95% CI, 0.845-0.987).", "source_id": "source_12", "study": "An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors", "support_kind": "bundle_reference", "url": "https://doi.org/10.1155/2023/7362551"}, {"cited_as": "Wang 2022a", "directness": "review", "doi": "10.1186/s12933-022-01542-4", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: The Food and Drug Administration has approved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors for the treatment of dyslipidemia. However, evidence of the optimal PCSK9 agents targeting PCSK9 for secondary prevention in patients with high-risk of cardiovascular events is lacking. Therefore, this study was conducted to evaluate the benefit and safety of different types of PCSK9 inhibitors. METHODS: Several databases including Cochrane Central, Ovid Medline, and Ovid Embase were searched from inception until March 30, 2022 without language restriction. Randomized controlled trials (RCTs) comparing administration of PCSK9 inhibitors with placebo or ezetimibe for secondary prevention of cardiovascular events in patients with statin-background therapy were identified. The primary efficacy outcome was all-cause mortality. The primary safety outcome was serious adverse events. RESULTS: Overall, nine trials totaling 54,311 patients were identified. Three types of PCSK9 inhibitors were evaluated. The use of alirocumab was associated with reductions in all-cause mortality compared with control (RR 0.83, 95% CrI 0.72-0.95).", "population": "not extracted", "quote": "The use of alirocumab was associated with reductions in all-cause mortality compared with control (RR 0.83, 95% CrI 0.72-0.95). Moreover, evolocumab was associated with increased all-cause mortality compared with alirocumab (RR 1.26, 95% CrI 1.04-1.52).", "source_id": "source_13", "study": "PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.1186/s12933-022-01542-4"}, {"cited_as": "Masson 2026", "directness": "review", "doi": "10.1007/s12325-025-03418-x", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "INTRODUCTION: Pharmacological inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is a well-established strategy for achieving substantial reductions in low-density lipoprotein cholesterol (LDL-C). Recently, novel oral PCSK9 inhibitors have emerged, providing new evidence regarding their lipid-lowering efficacy and safety. METHODS: This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. Randomized clinical trials evaluating oral PCSK9 inhibitors and reporting percentage changes in lipid parameters and/or adverse events were included. A qualitative synthesis was performed for all studies meeting predefined eligibility criteria, followed by a quantitative synthesis of studies with sufficient data for statistical pooling. RESULTS: Seven randomized clinical trials were included in the qualitative analysis, of which four were eligible for meta-analysis. Five oral PCSK9 inhibitors were identified. Three agents (MK-0616, AZD0780, and NNC0385-0434) contributed to the quantitative analysis, while two (DC371739 and CVI-LM001) were assessed descriptively.", "population": "not extracted", "quote": "Compared with placebo, oral PCSK9 inhibitors significantly reduced LDL-C [mean difference (MD) - 55.7; 95% confidence interval (CI) - 59.3 to - 52.1; I 2 = 14%)] and apolipoprotein B (MD - 46.9; 95% CI - 54.6 to - 39.2; I 2 = 72.9%). They also lowered non-high-density lipoprotein cholestero (MD - 49.4; 95% CI - 57.4 to - 41.5; I 2 = 50.3%), triglycerides (MD - 13.2; 95% CI - 21.4 to - 5.0; I 2 = 0%), and lipoprotein(a) (MD - 24.9; 95% CI - 34.9 to - 15.0; I 2 = 77.6%).", "source_id": "source_14", "study": "Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.1007/s12325-025-03418-x"}, {"cited_as": "Chen 2026", "directness": "direct", "doi": "10.1136/bmjopen-2025-112947", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "The background evidence for pcsk9 inhibitors effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Karatasakis 2017 [bundle:31], Chen 2026 [bundle:15], Gong 2025 [bundle:26] are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.", "excerpt": "INTRODUCTION: The 'strike early and strike strong' lipid-lowering strategy emphasises rapid reduction of low-density lipoprotein cholesterol (LDL-C) in patients with acute coronary syndrome (ACS). Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are increasingly used alongside statins to achieve guideline-recommended LDL-C targets after ACS. However, despite substantial LDL-C reductions with early PCSK9i initiation, their effects on non-culprit coronary atherosclerotic plaques remain unclear. This study aims to assess the impact of early intensive LDL-C lowering with PCSK9i added to moderate-intensity statin therapy on optical coherence tomography (OCT)-derived plaque characteristics in non-culprit coronary lesions in patients with ACS. METHODS AND ANALYSIS: In this prospective, multicentre, open-label trial, 212 patients with ACS will be randomised 1:1 to an early intensified lipid-lowering strategy (PCSK9i added to moderate-intensity statin) or guideline-directed medical therapy for 6 months. Serial OCT imaging of non-culprit coronary arteries with 20-70% stenosis will be performed at baseline and 6 months.", "population": "not extracted", "quote": "The primary endpoint will be analysed using analysis of covariance, adjusting for treatment group, baseline LDL-C stratification (≥1.8 vs <1.8 mmol/L), and baseline minimum FCT. 1 Because non-culprit plaques are prone to rupture and thrombosis, patients with ACS remain at elevated risk of recurrent cardiovascular events, especially during the first 30 to 90 days after discharge.", "source_id": "source_15", "study": "PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial", "support_kind": "bundle_reference", "url": "https://doi.org/10.1136/bmjopen-2025-112947"}, {"cited_as": "Jiang 2025", "directness": "review", "doi": "10.3389/fcvm.2024.1415668", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: The objective of this study is to assess the relative efficacy of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as alirocumab, evolocumab, and inclisiran, in conjunction with potent statins like atorvastatin and rosuvastatin, in patients presenting with hyperlipidemia or heightened cardiovascular risk attributable to elevated low-density lipoprotein cholesterol (LDL-C). METHODS: A systematic search was conducted across databases including PubMed, Embase, and the Cochrane Library to explore lipid-lowering therapies in hyperlipidemia from their inception to 7 November 2023. A network meta-analysis (NMA) was conducted via Stata 17 software, with two authors independently conducting the search, screening, and data abstraction. RESULTS: A total of 68 clinical studies involving 21,288 patients with hyperlipidemia were incorporated into the NMA. PSCK9 inhibitors and potent statins significantly reduced LDL-C levels from baseline vs. placebo regardless of background therapy. Regarding the efficacy of lipid reduction, four principal medications were evaluated: evolocumab and atorvastatin [mean standard deviation (MD) -3.41, 95% CI -4.81 to -2.", "population": "not extracted", "quote": "Meanwhile, compared with placebo, evolocumab (MD -1.89, 95% CI -2.27 to -1.50), alirocumab (MD -1.83, 95% CI -2.09 to -1.57), rosuvastatin (MD -1.93, 95% CI -2.30 to -1.56), inclisiran (MD -1.68, 95% CI -2.10 to -1.27), and atorvastatin (MD -1.68, 95% CI -2.04 to -1.31) could also play a role in the treatment of LDL-C reduction. Moreover, the incidence of adverse events (AEs) was similar to that observed in the control group, which included both placebo and potent statin groups, with no significant differences identified in our study ( P > 0.05).", "source_id": "source_16", "study": "Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.3389/fcvm.2024.1415668"}, {"cited_as": "Li 2024", "directness": "review", "doi": "10.3389/fcvm.2024.1375040", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD), a leading cause of global fatalities, has inconsistent findings regarding the impact of muscle symptoms despite promising clinical trials involving PCSK9 inhibitors (PCSK9i) and siRNA as potential therapeutic options. METHODS: The databases EMBASE, PubMed, Web of Science, Cochrane, and ClinicalTrials.gov were thoroughly searched without any restrictions on language. Review Manager 5.3 software was utilized to calculate relative risks with 95% confidence intervals (CIs) for dichotomous data and mean differences or standardized mean differences with 95%CIs for continuous data. To evaluate publication bias, Egger's test was employed using Stata/SE software. RESULTS: This analysis included 26 studies comprising 28 randomized controlled trials (RCTs) involving a total of 100,193 patients, and 4 different lipid-lowering therapy combinations. For events with creatine kinase >3ULN, evolocumab and alirocumab demonstrated significant advantages compared to inclisiran. Evolocumab showed the best results in terms of both new muscle symptom events and creatine kinase >3ULN.", "population": "not extracted", "quote": "Review Manager 5.3 software was utilized to calculate relative risks with 95% confidence intervals (CIs) for dichotomous data and mean differences or standardized mean differences with 95%CIs for continuous data. According to the 2018 AHA/ACC guideline and the 2017 National Lipid Association update, PCSK9 inhibitors were recommended for patients with LDL-C levels ≥70 mg/dl or non-high-density lipoprotein cholesterol (non-HDL-C) ≥100 mg/dl after maximally tolerated LDL-lowering therapies ( 8 , 9 ).", "source_id": "source_17", "study": "PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a systematic review and network meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.3389/fcvm.2024.1375040"}, {"cited_as": "Bosco 2025", "directness": "indirect", "doi": "10.1186/s12967-025-07432-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Familial hypercholesterolemia (FH) is characterized by lifelong elevated LDL-C levels and increased cardiovascular risk. PCSK9 inhibitors (PCSK9i) reduce LDL-C and Lp(a), however, the effect of dual lipid reduction on mechanical vascular function remains unclear. The aim of this study was to evaluate the efficacy of PCSK9i in reducing LDL-C and Lp(a) and to assess the relationship between the dual lipid reduction and the mechanical vascular profile improvement in FH subjects. METHODS: This prospective observational study included 301 genetically confirmed FH subjects treated with PCSK9i added to high-intensity statins and ezetimibe. Biochemical and PWV measurements were performed at baseline and after six months. Subjects were stratified into four groups based on median values of ΔLDL-C and ΔLp(a). RESULTS: After six months of add-on PCSK9i, 44.9% of FH subjects achieved their LDL-C targets. Reductions were observed in LDL-C (− 49.8%, p < 0.001), Lp(a) (− 21.4%, p < 0.001), and PWV (Δ − 22.7%, p < 0.001). PWV improvement increased across groups with greater lipid reductions (p for trend < 0.01); Group 3 and Group 4 exhibited a similar mechanical vascular benefit.", "population": "not extracted", "quote": "Evidence from phase III trials with PCSK9 monoclonal antibodies (PCSK9-mAb) such as alirocumab and evolocumab has demonstrated that an LDL-C reduction of 50-60% is associated with a lower rate of cardiovascular events [ 6 , 7 ]. FOURIER Outcomes and ODYSSEY OUTCOMES trials showed an Lp(a) reduction of 20-25% with PCSK9-mAb that was associated with a lower incidence of cardiovascular events [ 17 , 18 ].", "source_id": "source_18", "study": "Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects", "support_kind": "bundle_reference", "url": "https://doi.org/10.1186/s12967-025-07432-z"}, {"cited_as": "Chen 2024", "directness": "review", "doi": "10.1186/s12891-024-07674-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent an effective strategy for reducing cardiovascular disease risk. Yet, PCSK9's impact on osteoporosis remains unclear. Hence, we employed Mendelian randomization (MR) analysis for examining PCSK9 inhibitor effects on osteoporosis. METHODS: Single nucleotide polymorphisms (SNPs) for 3-hydroxy-3-methylglutaryl cofactor A reductase (HMGCR) and PCSK9 were gathered from available online databases for European pedigrees. Four osteoporosis-related genome-wide association studies (GWAS) data served as the main outcomes, and coronary artery disease (CAD) as a positive control for drug-targeted MR analyses. The results of MR analyses examined by sensitivity analyses were incorporated into a meta-analysis for examining causality between PCSK9 and HMGCR inhibitors and osteoporosis. RESULTS: The meta-analysis involving a total of 1,263,102 subjects, showed that PCSK9 inhibitors can increase osteoporosis risk (P < 0.05, I 2 , 39%). However, HMGCR inhibitors are not associated with osteoporosis risk.", "population": "not extracted", "quote": "The meta-analysis involving a total of 1,263,102 subjects, showed that PCSK9 inhibitors can increase osteoporosis risk ( P < 0.05, I 2 , 39%). It has been shown that these medications may considerably lower mortality in CAD patients by up to 30%.", "source_id": "source_19", "study": "PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.1186/s12891-024-07674-w"}, {"cited_as": "Zhang 2025", "directness": "review", "doi": "10.1371/journal.pone.0329676", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs used for the treatment of dyslipidemia. PCSK9 inhibitors have been shown to remarkably reduce cardiovascular events in patients at high risk, but data on their impact on sudden cardiac death (SCD) and ventricular arrhythmias are limited. This study aimed to evaluate whether PCSK9 inhibitor therapy reduces the risk of SCD and ventricular arrhythmias. METHODS: PubMed and Embase were searched up to September 1, 2024 and combined with data from ClinicalTrials.gov. Randomized controlled trials of PCSK9 inhibitors with ≥ 450 patients and follow-up of ≥ 48 weeks were considered for inclusion. Primary outcomes were the incidence of SCD and ventricular arrhythmias. We used a random-effects model to synthesize the data, calculating risk ratio (RR) and 95% confidence intervals (CI). Heterogeneity between studies was assessed with I² statistics. Risk of bias was assessed using the Cochrane risk of bias tool. RESULTS: A total of 12 articles with 16 trials involving 90,764 patients were included. The follow-up duration ranged from 48 weeks to 3.4 years.", "population": "not extracted", "quote": "Randomized controlled trials of PCSK9 inhibitors with ≥ 450 patients and follow-up of ≥ 48 weeks were considered for inclusion. PCSK9 inhibitor therapy did not significantly reduce the risk of SCD (RR 0.83, 95% CI 0.54-1.28; P = 0.40; I 2 = 0%), ventricular arrhythmias (RR 0.81, 95% CI 0.60-1.09; P = 0.17; I 2 = 0%), and cardiac arrest (RR 1.20, 95% CI 0.61-2.33; P = 0.60; I 2 = 0%).", "source_id": "source_20", "study": "Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A meta-analysis of randomized controlled trials", "support_kind": "bundle_reference", "url": "https://doi.org/10.1371/journal.pone.0329676"}, {"cited_as": "Barbati 2024", "directness": "indirect", "doi": "10.1371/journal.pone.0309470", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Low-Density Lipoprotein (LDL) cholesterol is one of the main target for cardiovascular (CV) prevention and therapy. In the last years, Proprotein Convertase Subtilisin-Kexin type 9 inhibitors (PCSK9-i) has emerged as a key therapeutic target to lower LDL and were introduced for prevention of CV events. Recently (June 2022) the Italian Medicines Agency (AIFA) modified the eligibility criteria for the use of PCSK9-i. We designed an observational study to estimate the prevalence of eligible subjects and evaluate the effectiveness of PCSK9-i applying a Target Trial Emulation (TTE) approach based on Electronic Health Records (EHR). Subjects meeting the eligibility criteria were identified from July 2017 (when PCSK9-i became available) to December 2020. Outcomes were all-cause death and the first hospitalization. Among eligible subjects, we identified those treated at date of the first prescription. Inverse Probability of Treatment Weights (IPTW) were estimated including demographic and clinical covariates, history of treatment with statins and the month/year eligibility date.", "population": "not extracted", "quote": "Inhibition of PCSK9 by the use of monoclonal antibodies has been demonstrated to significantly reduce LDL values (Low-Density Lipoprotein) by 50-70%, regardless of the therapeutic background in which it is implemented (monotherapy or in combination with the standard Lipid-Lowering Therapy, LLT) [ 6 ]. Moreover, in addition to the Average Treatment Effect (ATE), the Conditional Average Treatment Effect (CATE) [ 17 ] was estimated to evaluate the absolute reduction of the risk of events in the mutually exclusive subgroups derived from the eligibility criteria as follows: Documented AtheroSclerotic CardioVascular event (ASCVD) as the only eligibility criteria (“ASCVD”) Diabetes with Target Organ Damage (TOD) or at least a Risk Factor (RF) among smoking or hypertension in absence of documented ASCVD (“Diabetes TOD/RF”) Diabetes with TOD or at least a Risk Factor (RF) in presence of documente", "source_id": "source_21", "study": "Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records", "support_kind": "bundle_reference", "url": "https://doi.org/10.1371/journal.pone.0309470"}, {"cited_as": "Seijas-Amigo 2023", "directness": "indirect", "doi": "10.1007/s40256-023-00604-6", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "INTRODUCTION: The cognitive safety of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) has been established in clinical trials, but not yet in real-world observational studies. We assessed the cognitive function in patients initiating PCSK9i, and differences in cognitive function domains, to analyze subgroups by the low-density lipoprotein cholesterol (LDL-C) achieved, and differences between alirocumab and evolocumab. METHODS: This has a multicenter, quasi-experimental design carried out in 12 Spanish hospitals from May 2020 to February 2023. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA). RESULTS: Among 158 patients followed for a median of 99 weeks, 52% were taking evolocumab and 48% alirocumab; the mean change from baseline in MoCA score at follow-up was + 0.28 [95% CI (- 0.17 to 0.73; p = 0.216)]. There were no significant differences in the secondary endpoints-the visuospatial/executive domain + 0.04 (p = 0.651), naming domain - 0.01 (p = 0.671), attention/memory domain + 0.01 (p = 0.945); language domain - 0.10 (p = 0.145), abstraction domain + 0.03 (p = 0.624), and orientation domain - 0.05 (p = 0.", "population": "not extracted", "quote": "Alirocumab and evolocumab are the first class of PCSK9i that demonstrated in randomized clinical trials the ability to reduce the LDL-C levels by about 60% [ 9 , 10 ]. Recently, in FOURIER-OLE [ 19 ], an open-label extension study with evolocumab and with a follow-up of 8.4 years, neurocognitive events with evolocumab in the long term did not exceed those reported for placebo-treated patients.", "source_id": "source_22", "study": "Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study", "support_kind": "bundle_reference", "url": "https://doi.org/10.1007/s40256-023-00604-6"}, {"cited_as": "Wang 2022b", "directness": "review", "doi": "10.3389/fcvm.2022.1016802", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: The efficacy of anti-proprotein convertase subtilisin/Kexin type 9 (PCSK9) monoclonal antibodies in patients with atherosclerotic cardiovascular disease (ASCVD) remains unclear. Therefore, this study aims to assess the effect of PCSK9 inhibitors (alirocumab and evolocumab) on ASCVD patients considering the number needed to treat (NNT). METHODS: We reviewed randomized controlled trials (RCTs) which compared the effects of alirocumab or evolocumab and placebo or standards of care. All articles were published in English up to May 2022. Using random effect models, we estimated risk ratios (RRs), NNT, and 95% confidence intervals (CI). RESULTS: We incorporated 12 RCTs with 53 486 patients total, of which 27 674 received PCSK9 inhibitors and 25 812 received placebos. The mean follow-up duration was 1.56 years. The effect of PCSK9 inhibitors on major adverse cardiovascular events (MACE) was statistically significant, and the corresponding mean NNT was 36. Alirocumab reduced the risk of MACE, stroke, and coronary revascularization; the corresponding mean NNT were 37, 319, and 107, respectively.", "population": "not extracted", "quote": "This study suggests that preventing one patient from MACE needed to treat 36 patients with ASCVD with PCSK9 inhibitors for 1.56 years. The effect of PCSK9 inhibitors on MACE was statistically significant (RR 0.83, 95% CI 0.79-0.87) ( Supplementary Figure 3 ), and the corresponding NNT was 36 (NNTB 29 to NNTB 47).", "source_id": "source_23", "study": "Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat", "support_kind": "bundle_reference", "url": "https://doi.org/10.3389/fcvm.2022.1016802"}, {"cited_as": "Akhtar 2025", "directness": "indirect", "doi": "10.1038/s41598-025-22916-0", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "We looked to establish if Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor therapy can be safely initiated in heart transplant recipients and effectively reduce target low density lipoprotein (LDL). This prospective audit reviewed heart transplant recipients between 1st June 2019 and 1st November 2022 at Harefield Hospital in London. At baseline all patients must have attempted statin and ezetimibe therapy. All patients who remained with an LDL > 3.5 with very high cardiovascular risk or LDL > 4.0mmol/L with high risk were initiated on alirocumab injection every 2 weeks. Monitoring including biochemical analysis including immunotherapy levels, troponin, brain natriuretic peptides, electrocardiograph and echocardiogram. PCKS9i therapy was tolerated in 9/11 patients with 2 stopping treatment, one due to nausea & vomiting and one due to elevation in creatinine kinase. No adverse effects related to the heart transplant were detected and no significant change in creatinine kinase, liver function or left ventricular ejection fraction were seen. A significant reduction in LDL, total cholesterol, triglycerides was seen with LDL cholesterol reduction of 55% from 4.14 ± 0.", "population": "not extracted", "quote": "Estimated treatment effects constant over time expects to reduce LDL by about 2.19 to 2.77 mmol/L with 95% probability. Total cholesterol is likely to be lowered by 2.22 to 2.91 mmol/L and triglycerides by 0.42 to1.6 mmol/L with the same probability.", "source_id": "source_24", "study": "PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre observational study", "support_kind": "bundle_reference", "url": "https://doi.org/10.1038/s41598-025-22916-0"}, {"cited_as": "Yu 2026", "directness": "indirect", "doi": "10.1161/JAHA.125.047923", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Combining PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors with statins significantly lowers low-density lipoprotein cholesterol and reduces cardiovascular events in patients with coronary heart disease versus statins alone. However, it remains unclear which monotherapy offers greater cardiovascular benefit. METHODS: This prospective non-randomized real-world observational cohort study enrolled coronary heart disease inpatients from July 2020 to March 2024. Patients received either alirocumab (75 mg/2 weeks) or statins (atorvastatin 20 mg/day or rosuvastatin 10 mg/day). The primary outcome was a composite of cardiovascular death, myocardial infarction, stroke, heart failure hospitalization, or coronary revascularization. Cox proportional hazards models and restricted mean survival time analyses were used. RESULTS: Among 1165 analyzed patients, 215 received PCSK9 inhibitors and 950 received statins. After 1 month, low-density lipoprotein cholesterol reduction was greater in the PCSK9 inhibitor group (from 2.57 to 0.75 mmol/L) than in the statin group (from 2.29 to 1.40 mmol/L; P <0.001). However, this difference was not significant at 12 months (1.", "population": "not extracted", "quote": "After 1 month, low‐density lipoprotein cholesterol reduction was greater in the PCSK9 inhibitor group (from 2.57 to 0.75 mmol/L) than in the statin group (from 2.29 to 1.40 mmol/L; P <0.001). Hypertension was defined as systolic blood pressure of ≥140 mm Hg and/or diastolic blood pressure of ≥90 mm Hg or current use of antihypertensive medication.", "source_id": "source_25", "study": "Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment", "support_kind": "bundle_reference", "url": "https://doi.org/10.1161/JAHA.125.047923"}, {"cited_as": "Gong 2025", "directness": "direct", "doi": "10.1186/s13063-024-08709-2", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "The background evidence for pcsk9 inhibitors effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Karatasakis 2017 [bundle:31], Chen 2026 [bundle:15], Gong 2025 [bundle:26] are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.", "excerpt": "BACKGROUND: Early neurological deterioration (END) is a critical determinant influencing the short-term prognosis of acute ischemic stroke (AIS) patients and is associated with increased mortality rates among hospitalized individuals. AIS frequently coexists with coronary heart disease (CHD), complicating treatment and leading to more severe symptoms and worse outcomes. Shared risk factors between CHD and AIS, especially elevated low-density lipoprotein cholesterol (LDL-C), contribute to atherosclerosis and inflammation, which worsen brain tissue damage. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer a promising treatment option. They effectively lower LDL-C levels and may help reduce END in AIS patients with CHD. This study aims to evaluate how effective PCSK9 inhibitors are in reducing END among this high-risk group and to provide new insights for treatment strategies. METHODS: This is a prospective, randomized, parallel-group, blinded-endpoint, single-center clinical study.", "population": "not extracted", "quote": "3.Inability to control severe hypertension (systolic blood pressure persistently ≥180 mmHg or diastolic blood pressure ≥110 mmHg after active treatment), severe infections (meeting criteria such as elevated body temperature ≥38°C, signs of shock, infection-related consciousness impairment, respiratory failure, and blood gas analysis PO 2 <60 mmH 2 O), or abnormal liver function (ALT > 100 IU/L or AST > 80 IU/L), renal dysfunction (glomerular filtration rate < 30 ml/min), or patients with bleeding tendencies in the blood system (platelets < 60×10 9 /L or APTT > 60 seconds or INR > 3). Secondary objectives include evaluating changes in daily living abilities, recurrence rates of cardiovascular and cerebrovascular events within 90 days, alterations in blood biochemical indices/markers, and variations in inflammatory factors between the two patient groups after treatment.", "source_id": "source_26", "study": "Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of coronary heart disease: a study protocol for a randomized controlled trial in Dalian, China", "support_kind": "bundle_reference", "url": "https://doi.org/10.1186/s13063-024-08709-2"}, {"cited_as": "Ray 2025", "directness": "review", "doi": "10.2174/011573403X345749250122092324", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "INTRODUCTION: Reducing the risk of atherosclerotic cardiovascular disease is the aim of lipid-lowering therapy (ASCVD). It is commonly acknowledged that low-density lipoprotein (LDL) is a major cause of ASCVD. Several online databases and search engines, such as Pub- Med and the Cochrane Library, were used to conduct a thorough search. METHODS: This study included RCTs assessing the effect of PCSK9 inhibitors on cardiovascular events. The RevMan 5.4 software was used to conduct the meta-analysis. This analysis included nine RCTs in total. RESULTS: Meta-analysis of the included studies showed that the levels of total cholesterol, LDL, and triglycerides were reduced after the use of PCSK9 inhibitors, and HDL levels were increased, which is good cholesterol. Most adverse cardiac events (MACE) were reduced after the use of PCSK9 inhibitors. CONCLUSION: In conclusion, ezetimibe, a PCSK9 inhibitor added to statin therapy, further reduces MACE risk without affecting all-cause mortality, even though statins already significantly reduce major adverse cardiovascular events (MACE) and mortality.", "population": "not extracted", "quote": "Methods: Publications in the English language that meet stress-related adaptation associated with an increased risk for cardiovascular disease guidelines, published within the past 5 years. Significant reductions in LDL-C were found with PCSK9 inhibitors compared with controls, with evolocumab and alirocumab showing LDL-C reductions of up o 72.9%.", "source_id": "source_27", "study": "The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.2174/011573403X345749250122092324"}, {"cited_as": "Theodorou 2025", "directness": "indirect", "doi": "10.1111/ene.70175", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND AND OBJECTIVES: Limited data exist on the efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and inclisiran among patients with neuromuscular disorders and statin-induced myotoxicity and/or hepatotoxicity. We assessed the safety and efficacy of PCSK9 inhibitors and inclisiran in this specific patient subgroup. METHODS: We conducted an observational cohort study evaluating patients with available clinical and laboratory data prior to and at prespecified time points following treatment initiation with PCSK9 inhibitors or inclisiran. RESULTS: Eleven patients with neuromuscular disorders and statin intolerance were included in this study. Median follow-up time after PCSK9 inhibitor or inclisiran initiation was 14 (9-17) months. PCSK9 inhibitors or inclisiran use led to a significant decrease in mean low-density lipoprotein cholesterol levels. Moreover, all patients tolerated these lipid-lowering agents without exacerbation of their underlying myositis, myopathy, neuromuscular junction disorder, and without presenting any adverse event or relapse of myotoxicity and/or hepatotoxicity.", "population": "not extracted", "quote": "PCSK9 inhibitors and inclisiran have been studied in patients with homozygous or heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease (ASCVD), and ASCVD risk equivalent (a high‐risk primary prevention cohort comprising individuals with type 2 diabetes mellitus, familial hypercholesterolemia, or a 10‐year risk of a CV event ≥ 20% [by Framingham Risk Score or equivalent]). During the first 3 months, mean LDL concentrations were significantly reduced (from 170.5 ± 52.0 mg/dL to 96.7 ± 20.6 mg/dL; p ‐value < 0.001) compared to baseline levels and during the following months remained stable at target levels (Figure 1A ).", "source_id": "source_28", "study": "Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin Intolerance", "support_kind": "bundle_reference", "url": "https://doi.org/10.1111/ene.70175"}, {"cited_as": "Ariyanti 2026", "directness": "review", "doi": "10.1080/03007995.2026.2662127", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: The role of PCSK9 inhibitors in PAD remains uncertain, despite their established benefits in atherosclerotic cardiovascular disease. This meta-analysis aimed to evaluate their effects on cardiovascular, functional, limb, and survival outcomes in PAD. METHODS: We systematically searched PubMed, Scopus, and ClinicalTrials.gov through August 2025 for RCTs and cohort studies comparing PCSK9 inhibitors with placebo or standard therapy in PAD. Primary outcomes were MACE and major amputation. Data were analyzed using fixed- or random-effects models depending on heterogeneity. RESULTS: Six studies (five RCTs, one cohort) involving 4,563 patients were included. PCSK9 inhibitors significantly reduced MACE (HR 0.77; 95% CI: 0.65 to 0.92) and lowered LDL-C levels (MD -55.76 mg/dL; 95% CI: -63.19 to -48.34). Positive but non-significant trends were observed for major amputation (HR 0.35; 95% CI: 0.11 to 1.07), all-cause mortality (HR 0.58; 95% CI: 0.26 to 1.30), and walking performance (SMD 2.38; 95% CI: -1.97 to 6.73).", "population": "not extracted", "quote": "PCSK9 inhibitors significantly reduced MACE (HR 0.77; 95% CI: 0.65 to 0.92) and lowered LDL-C levels (MD -55.76 mg/dL; 95% CI: -63.19 to -48.34). Positive but non-significant trends were observed for major amputation (HR 0.35; 95% CI: 0.11 to 1.07), all-cause mortality (HR 0.58; 95% CI: 0.26 to 1.30), and walking performance (SMD 2.38; 95% CI: -1.97 to 6.73).", "source_id": "source_29", "study": "Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in peripheral artery disease-a systematic review and meta-analysis.", "support_kind": "bundle_reference", "url": "https://doi.org/10.1080/03007995.2026.2662127"}, {"cited_as": "Hu 2025", "directness": "review", "doi": "10.1097/mca.0000000000001464", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease due to its unique apo(a) component and its association with atherosclerosis and thrombogenesis. This meta-analysis was conducted to evaluate the effects of PCSK9 inhibitors on major adverse cardiac events (MACE) and Lp(a) levels in patients with coronary heart disease. METHODS: Randomized controlled trials (RCTs) were systematically searched in PubMed, the Cochrane Library, and other databases. Stata 15.1 software was used for data analysis, and a random- or fixed-effects model was selected based on inter-study heterogeneity. Egger's test was applied to detect publication bias. RESULTS: A total of 12 RCTs were included, involving 48 116 patients with a mean age of 62 years, comprising 65% males and diverse ethnic backgrounds. The results showed that compared with the control group, PCSK9 inhibitors significantly reduced low-density lipoprotein cholesterol (WMD = -1.24 mmol/L, 95% confidence interval (CI): -1.28 to -1.20), total cholesterol, triglycerides, and Lp(a) levels while increasing high-density lipoprotein cholesterol levels.", "population": "not extracted", "quote": "The results showed that compared with the control group, PCSK9 inhibitors significantly reduced low-density lipoprotein cholesterol (WMD = -1.24 mmol/L, 95% confidence interval (CI): -1.28 to -1.20), total cholesterol, triglycerides, and Lp(a) levels while increasing high-density lipoprotein cholesterol levels. For MACE, PCSK9 inhibitors significantly reduced the risk of nonfatal myocardial infarction, stroke, and coronary revascularization events (RR = 0.87, 95% CI: 0.84-0.89).", "source_id": "source_30", "study": "Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a meta-analysis.", "support_kind": "bundle_reference", "url": "https://doi.org/10.1097/mca.0000000000001464"}, {"cited_as": "Karatasakis 2017", "directness": "direct", "doi": "10.1161/JAHA.117.006910", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "The background evidence for pcsk9 inhibitors effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Karatasakis 2017 [bundle:31], Chen 2026 [bundle:15], Gong 2025 [bundle:26] are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.", "excerpt": "BACKGROUND: We sought to examine the efficacy and safety of 2 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors: alirocumab and evolocumab. METHODS AND RESULTS: We performed a systematic review and meta-analysis of randomized controlled trials comparing treatment with and without PCSK9 inhibitors; 35 randomized controlled trials comprising 45 539 patients (mean follow-up: 85.5 weeks) were included. Mean age was 61.0±2.8 years, and mean baseline low-density lipoprotein cholesterol was 106±22 mg/dL. Compared with no PCSK9 inhibitor therapy, treatment with a PCSK9 inhibitor was associated with a lower rate of myocardial infarction (2.3% versus 3.6%; odds ratio [OR]: 0.72 [95% confidence interval (CI), 0.64-0.81]; P <0.001), stroke (1.0% versus 1.4%; OR: 0.80 [95% CI, 0.67-0.96]; P =0.02), and coronary revascularization (4.2% versus 5.8%; OR: 0.78 [95% CI, 0.71-0.86]; P <0.001). Overall, no significant change was observed in all-cause mortality (OR: 0.71 [95% CI, 0.47-1.09]; P =0.12) or cardiovascular mortality (OR: 1.01 [95% CI, 0.85-1.19]; P =0.95).", "population": "not extracted", "quote": "We performed a systematic review and meta‐analysis of randomized controlled trials comparing treatment with and without PCSK9 inhibitors; 35 randomized controlled trials comprising 45 539 patients (mean follow‐up: 85.5 weeks) were included. Compared with no PCSK9 inhibitor therapy, treatment with a PCSK9 inhibitor was associated with a lower rate of myocardial infarction (2.3% versus 3.6%; odds ratio [OR]: 0.72 [95% confidence interval (CI), 0.64-0.81]; P <0.001), stroke (1.0% versus 1.4%; OR: 0.80 [95% CI, 0.67-0.96]; P =0.02), and coronary revascularization (4.2% versus 5.8%; OR: 0.78 [95% CI, 0.71-0.86]; P <0.001).", "source_id": "source_31", "study": "Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials", "support_kind": "bundle_reference", "url": "https://doi.org/10.1161/JAHA.117.006910"}, {"cited_as": "Kuhl 2019", "directness": "indirect", "doi": "10.1371/journal.pone.0210373", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Hypercholesterolaemia is common in patients after cardiac transplantation. Monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) reduce low-density lipoprotein (LDL) cholesterol levels and subsequently the risk of cardiovascular events in patients with dyslipidaemia. There are no published data on the effect of this medication class on cholesterol levels in patients after cardiac transplantation. METHODS: In this retrospective study we investigated patients who were treated with PCSK9 inhibitors either because of intolerance of statins or residual hypercholesterolaemia with evidence of cardiac allograft vasculopathy. We compared the data of patients prior to the start with these medications with their most recent dataset. RESULTS: Ten patients (nine men; mean age 58±6 years) underwent cardiac transplantation 8.3±4.5 (range 3-15) years ago. The treatment duration of Evolocumab or Alirocumab was on average 296±125 days and lead to a reduction of total Cholesterol (281±52 mg/dl to 197±36 mg/dl; p = 0.002) and LDL Cholesterol (170±22 mg/dl to 101±39 mg/dl; p = 0.001).", "population": "not extracted", "quote": "The effect of PCSK9 therapy differed between individual patients and ranged from a 26% increase to a 66% decrease of LDL ( Fig 1 ). Therapy with PCSK9 inhibitors resulted in an overall LDL cholesterol reduction of 40%.", "source_id": "source_32", "study": "Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation", "support_kind": "bundle_reference", "url": "https://doi.org/10.1371/journal.pone.0210373"}, {"cited_as": "Du 2019", "directness": "review", "doi": "10.1136/heartjnl-2019-314763", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: To evaluate the effects of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors on major adverse cardiovascular events (MACE). METHODS: Our systematic review included randomised controlled trials if they studied PCSK9 inhibitors in patients for primary and/or secondary prevention of cardiovascular diseases or with hypercholesterolaemia/hyperlipidaemia. Dichotomous variables from individual studies were pooled by relative risks (RR) and their 95% CIs using the random-effect model. Risk difference (RD) in the 10-year frame was also estimated using the pooled RR and the estimated baseline risk using the control group. Grading of Recommendation Assessment, Development and Evaluation was used to assess the quality of evidence. RESULTS: We included 54 trials with 97 910 patients in the analysis. Compared with controls, PCSK9 inhibitors significantly reduced the risk of MACE by 16% (RR, 0.84; 95% CI 0.79 to 0.89; RD: 47 fewer per 1000 vs 286 as the baseline risk; 95% CI 32 to 59 fewer), non-fatal myocardial infarction (MI) by 17% (RR, 0.83; 95% CI 0.74 to 0.93; RD, 35 fewer per 1000 vs 207 as the baseline; 95% CI 13 to 53 fewer) and any stroke by 25% (RR, 0.", "population": "not extracted", "quote": "Dichotomous variables from individual studies were pooled by relative risks (RR) and their 95% CIs using the random-effect model. Compared with controls, PCSK9 inhibitors significantly reduced the risk of MACE by 16% (RR, 0.84; 95% CI 0.79 to 0.89; RD: 47 fewer per 1000 vs 286 as the baseline risk; 95% CI 32 to 59 fewer), non-fatal myocardial infarction (MI) by 17% (RR, 0.83; 95% CI 0.74 to 0.93; RD, 35 fewer per 1000 vs 207 as the baseline; 95% CI 13 to 53 fewer) and any stroke by 25% (RR, 0.75; 95% CI 0.65 to 0.85; RD, 16 fewer per 1000 vs 61 as the baseline; 95% CI 9 to 21 fewer) with moderate quality evidence.", "source_id": "source_33", "study": "Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis.", "support_kind": "bundle_reference", "url": "https://doi.org/10.1136/heartjnl-2019-314763"}, {"cited_as": "Khan 2018", "directness": "review", "doi": "10.1177/2047487318766612", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Background The comparative effects of statins, ezetimibe with or without statins and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors remain unassessed. Design Bayesian network meta-analysis was conducted to compare treatment groups. Methods Thirty-nine randomized controlled trials were selected using MEDLINE, EMBASE, and CENTRAL (inception - September 2017). Results In network meta-analysis of 189,116 patients, PCSK9 inhibitors were ranked as the best treatment for prevention of major adverse cardiovascular events (Surface Under Cumulative Ranking Curve (SUCRA), 85%), myocardial infarction (SUCRA, 84%) and stroke (SUCRA, 80%). PCSK9 inhibitors reduced the risk of major adverse cardiovascular events compared with ezetimibe + statin (odds ratio (OR): 0.72; 95% credible interval (CrI), 0.55-0.95; Grading of Recommendation Assessment, Development and Evaluation (GRADE) criteria: moderate), statin (OR: 0.78; 95% CrI: 0.62-0.97; GRADE: moderate) and placebo (OR: 0.63; 95% CrI: 0.49-0.79; GRADE: high). The PCSK9 inhibitors were consistently superior to groups for major adverse cardiovascular event reduction in secondary prevention trials (SUCRA, 95%).", "population": "not extracted", "quote": "Results In network meta-analysis of 189,116 patients, PCSK9 inhibitors were ranked as the best treatment for prevention of major adverse cardiovascular events (Surface Under Cumulative Ranking Curve (SUCRA), 85%), myocardial infarction (SUCRA, 84%) and stroke (SUCRA, 80%). PCSK9 inhibitors reduced the risk of major adverse cardiovascular events compared with ezetimibe + statin (odds ratio (OR): 0.72; 95% credible interval (CrI), 0.55-0.95; Grading of Recommendation Assessment, Development and Evaluation (GRADE) criteria: moderate), statin (OR: 0.78; 95% CrI: 0.62-0.97; GRADE: moderate) and placebo (OR: 0.63; 95% CrI: 0.49-0.79; GRADE: high).", "source_id": "source_34", "study": "A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.", "support_kind": "bundle_reference", "url": "https://doi.org/10.1177/2047487318766612"}, {"cited_as": "Turgeon 2018", "directness": "review", "doi": "10.1016/j.cjca.2018.04.002", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are efficacious lipid-lowering agents, but more precise estimates of their effects on major adverse cardiovascular events (MACE), mortality, and safety are needed. We systematically reviewed and meta-analyzed randomized controlled trials with durations ≥ 6 months comparing MACE, mortality, and safety with PCSK9 inhibitors vs control. We searched CENTRAL, Embase, MedLine and the grey literature to November 7, 2018. From 2048 articles, we included 23 trials (n = 60,723). PCSK9 inhibitors reduced MACE (relative risk, 0.83; 95% confidence interval, 0.78-0.88), but did not clearly reduce mortality (relative risk, 0.93; 95% confidence interval, 0.85-1.02) or increase adverse events. In conclusion, PCSK9 inhibitors reduce nonfatal MACE, are well tolerated, but effects on mortality remain unclear.", "population": "not extracted", "quote": "We systematically reviewed and meta-analyzed randomized controlled trials with durations ≥ 6 months comparing MACE, mortality, and safety with PCSK9 inhibitors vs control. PCSK9 inhibitors reduced MACE (relative risk, 0.83; 95% confidence interval, 0.78-0.88), but did not clearly reduce mortality (relative risk, 0.93; 95% confidence interval, 0.85-1.02) or increase adverse events.", "source_id": "source_35", "study": "Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial.", "support_kind": "bundle_reference", "url": "https://doi.org/10.1016/j.cjca.2018.04.002"}, {"cited_as": "Schmidt 2017", "directness": "review", "doi": "10.1002/14651858.cd011748.pub2", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Despite the availability of effective drug therapies that reduce low-density lipoprotein (LDL)-cholesterol (LDL-C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL-C reduction may be warranted, especially for patients who are unresponsive to, or unable to take, existing LDL-C-reducing therapies. By inhibiting the proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme, monoclonal antibodies (PCSK9 inhibitors) may further reduce LDL-C, potentially reducing CVD risk as well. OBJECTIVES: Primary To quantify short-term (24 weeks), medium-term (one year), and long-term (five years) effects of PCSK9 inhibitors on lipid parameters and on the incidence of CVD. Secondary To quantify the safety of PCSK9 inhibitors, with specific focus on the incidence of type 2 diabetes, cognitive function, and cancer. Additionally, to determine if specific patient subgroups were more or less likely to benefit from the use of PCSK9 inhibitors. SEARCH METHODS: We identified studies by systematically searching the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and Web of Science.", "population": "not extracted", "quote": "Primary To quantify short-term (24 weeks), medium-term (one year), and long-term (five years) effects of PCSK9 inhibitors on lipid parameters and on the incidence of CVD. We compared PCSK9 inhibitors with placebo (thirteen RCTs), ezetimibe (two RCTs) or ezetimibe and statins (five RCTs).Compared with placebo, PCSK9 inhibitors decreased LDL-C by 53.86% (95% confidence interval (CI) 58.64 to 49.08; eight studies; 4782 participants; GRADE: moderate) at 24 weeks; compared with ezetimibe, PCSK9 inhibitors decreased LDL-C by 30.20% (95% CI 34.18 to 26.23; two studies; 823 participants; GRADE: moderate), and compared with ezetimibe and statins, PCSK9 inhibitors decreased LDL-C by 39.20% (95% CI 56.15 to 22.26; five studies; 5376 participants; GRADE: moderate).Compared with placebo, PCSK9 inhibitors decreased the risk of CVD events, with a risk difference (RD) of 0.91% (odds ratio (OR) of 0.86, ", "source_id": "source_36", "study": "PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.", "support_kind": "bundle_reference", "url": "https://doi.org/10.1002/14651858.cd011748.pub2"}], "claim": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "claim_id": "claim_27"}, {"candidate_sources": [], "citation_support": [{"cited_as": "Hosseini 2024", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.1186/s12872-024-04057-w"}, {"cited_as": "Hollstein 2021", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "bundle_reference", "url": "https://doi.org/10.1007/s40256-020-00411-3"}, {"cited_as": "Imran 2023", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.1371/journal.pone.0295359"}, {"cited_as": "Scicali 2021", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "bundle_reference", "url": "https://doi.org/10.1007/s00592-021-01703-z"}, {"cited_as": "Rehues 2023", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "bundle_reference", "url": "https://doi.org/10.3390/ijms24032319"}, {"cited_as": "Cao 2025", "directness": "review", "doi": "10.3389/fcvm.2025.1612095", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Few percutaneous coronary intervention (PCI) patients achieve low-density lipoprotein cholesterol (LDL-C) targets with statins alone. While proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors effectively diminish LDL-C levels, their combined use with statins for reducing major adverse cardiovascular events (MACE) and improving lipid profiles post-PCI requires further validation. This study seeks to appraise the therapeutic impact of PCSK9 inhibitors combined with statins on MACE and blood lipids in patients following PCI. METHODS: Randomized controlled trials (RCTs) and cohort studies as of February 2025 in the PubMed, Embase, Cochrane Library, and Web of Science databases were identified. Regarding the risk of bias evaluation, Cochrane ROB 2.0 was employed for RCTs. Moreover, cohort studies were appraised by means of the Newcastle-Ottawa Scale. In terms of heterogeneity, it was appraised by means of the I 2 statistics. The relative risk (RR) and 95% confidence interval (CI) for dichotomous variables, along with the weighted mean difference (WMD), standardized mean difference (SMD), and their respective 95% CIs for continuous variables.", "population": "not extracted", "quote": "The relative risk (RR) and 95% confidence interval (CI) for dichotomous variables, along with the weighted mean difference (WMD), standardized mean difference (SMD), and their respective 95% CIs for continuous variables. The meta-analysis revealed that, against the statin group, the combination therapy group displayed a notable decline in MACE incidence (RR: 0.61; 95% CI: 0.50-0.75; p < 0.001; I 2 = 0.0%).", "source_id": "source_6", "study": "Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in patients after percutaneous coronary intervention: a systematic review and meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.3389/fcvm.2025.1612095"}, {"cited_as": "Liu 2024", "directness": "review", "doi": "10.3389/fcvm.2024.1454918", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: In recent years, the position of PCSK9 inhibitors as adjuvant therapy to statins in guidelines has further improved. However, there remained a dearth of direct comparative studies among different PCSK9 inhibitors. Therefore, this study aimed to conduct a network meta-analysis to evaluate the efficacy and safety of different PCSK9 inhibitors combined with statins. METHODS: A comprehensive literature search was conducted from the study's inception to 12 November 2023, encompassing multiple online databases including PubMed, Embase, Cochrane Central, Web of Science, and ClinicalTrials.gov to obtain relevant randomized controlled trials. Frequentist network meta-analysis was employed to compare the efficacy and safety of different PCSK9 inhibitors. The efficacy endpoints were low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and lipoprotein (a) (Lp(a)). The safety endpoints were any adverse events (AE), severe adverse events (SAE), AE leading to treatment discontinuation, and injection-site reaction. RESULTS: Compared with placebo and ezetimibe, all PCSK9 inhibitors demonstrated significant reductions in LDL-C levels.", "population": "not extracted", "quote": "Notably, evolocumab exhibited the most pronounced effect with a treatment difference of -63.67% (-68.47% to -58.87%) compared with placebo. Compared with placebo, it can reduce LDL-C levels by approximately 57%-65%, maintain long-term treatment efficacy, and exhibit strong lipid-lowering abilities for ApoB and Lp(a) ( 25 - 27 ).", "source_id": "source_7", "study": "The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.3389/fcvm.2024.1454918"}, {"cited_as": "Jing 2025", "directness": "indirect", "doi": "10.1038/s41598-025-26495-y", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "PROMIS effectively assesses patient health, but its use in evaluating the quality of life in acute coronary syndrome (ACS) patients on PCSK9 inhibitors (PCSK9i) remains unexplored. This study examined the impact of PCSK9i on quality of life in ACS patients, comparing PCSK9i plus statin versus statin-only therapy using PROMIS-10, and analyzed the association between PROMIS scores and major adverse cardiovascular events (MACE). The EMSIACS trial is a prospective, randomized, open-label, parallel-group, multicenter study registered at ClinicalTrials.gov (NCT04100434). This paper presents the exploratory outcomes of this trial. From September 2020 to March 2022, a total of 500 ACS patients were enrolled. Patients were randomly assigned in a 1:1 ratio to receive Evolocumab plus statin therapy or statin-only therapy. The quality of life was assessed using PROMIS 10 at baseline, week 12, and week 48. PROMIS 10 includes two summary scores: Global Physical Health (GPH, including physical health, physical function, fatigue and pain intensity) and Global Mental Health (GMH, including overall quality of life, mental health, satisfaction with social activities, and emotional problems).", "population": "not extracted", "quote": "At week 12, Evolocumab significantly improved Global Physical Health (GPH) ( P < 0.001) and Global Mental Health (GMH) scores ( P < 0.001), particularly in pain intensity, mental health, and social activity satisfaction ( P < 0.001). By week 48, both groups improved significantly from baseline, with no significant differences between them(GPH: P = 0.120; GMH: P = 0.105).", "source_id": "source_8", "study": "Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of the EMSIACS trial", "support_kind": "bundle_reference", "url": "https://doi.org/10.1038/s41598-025-26495-y"}, {"cited_as": "Raone 2025", "directness": "review", "doi": "10.1007/s40256-025-00778-1", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Residual cardiovascular risk remains substantial in patients with atherosclerotic cardiovascular disease (ASCVD) despite high-intensity statin therapy. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), including monoclonal antibodies and small-interfering RNA agents, offer additional risk reduction, yet comparative evidence across individual regimens remains limited. METHODS AND RESULTS: We conducted a systematic review and network meta-analysis of randomized controlled trials evaluating approved PCSK9i dosages in patients with ASCVD. The primary outcome was major adverse cardiovascular events (MACE); the secondary outcomes included myocardial infarction, stroke, coronary revascularization, cardiovascular mortality, and all-cause death. A total of eight trials involving 49,847 patients were included. Evolocumab (140 mg every 2 weeks or 420 mg monthly) and alirocumab 150 mg every 2 weeks significantly reduced MACE compared with placebo (risk ratios (RR): 0.78, 95% confidence intervals (CI): 0.66-0.93 and RR: 0.47, 95% CI 0.25-0.86, respectively). Evolocumab was also associated with reductions in myocardial infarction, stroke, and revascularization.", "population": "not extracted", "quote": "Evolocumab (140 mg every 2 weeks or 420 mg monthly) and alirocumab 150 mg every 2 weeks significantly reduced MACE compared with placebo (risk ratios (RR): 0.78, 95% confidence intervals (CI): 0.66-0.93 and RR: 0.47, 95% CI 0.25-0.86, respectively). Alirocumab 150 mg demonstrated the most pronounced effect on revascularization and was superior to both evolocumab and the lower alirocumab dose in this outcome.", "source_id": "source_9", "study": "Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.1007/s40256-025-00778-1"}, {"cited_as": "Song 2024", "directness": "review", "doi": "10.1097/MD.0000000000038360", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: The effect of proprotein convertase subtilisin kexin type (PCSK9) inhibitors on blood lipids and major adverse cardiovascular events (MACEs) is still controversial for acute coronary syndrome (ACS) patients. This study aimed to evaluate the efficacy and safety of PCSK9 inhibitors for ACS patients. METHODS: We searched the following databases until March 2023: PubMed, Embase, Cochrane, Web of Science, CNKI, Chongqing VIP Database and Wan Fang Database. Finally, all randomized controlled trials, retrospective studies and prospective studies were included in the analysis. RESULTS: A total of 20 studies involving 48,621 patients were included in this meta-analysis. The results demonstrated that PCSK9 inhibitors group was more beneficial for ACS patients compared to control group (receiving statins alone or placebo). The meta-analysis showed: there was no significant difference in high density lipoprotein cholesterol between PCSK9 inhibitors group and control group (standard mean difference = 0.17, 95% confidence interval [CI]: -0.02 to 0.36, P = .", "population": "not extracted", "quote": "The meta-analysis showed: there was no significant difference in high density lipoprotein cholesterol between PCSK9 inhibitors group and control group (standard mean difference = 0.17, 95% confidence interval [CI]: -0.02 to 0.36, P = .08), while the level of low density lipoprotein cholesterol in PCSK9 inhibitors group was lower than that in control group (standard mean difference = -2.32, 95% CI: -2.81 to -1.83, P < .00001). Compared with the control group, the PCSK9 inhibitors group also decreased the levels of total cholesterol and triglycerides (mean difference = -1.24, 95% CI: -1.40 to -1.09, P < .00001, mean difference = -0.36, 95% CI: -0.56 to -0.16, P = .0004).", "source_id": "source_10", "study": "Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary syndrome: A systematic review and meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.1097/MD.0000000000038360"}, {"cited_as": "Xiao 2024", "directness": "review", "doi": "10.3390/medicina60101646", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Background and Objectives : The proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab are recently developed promising drugs used for treatment of familial hypercholesterolemia (FH). This systematic review and meta-analysis aimed to thoroughly evaluate the efficacy and safety of evolocumab and alirocumab among pediatric patients with FH. Materials and Methods : A comprehensive search was conducted in PubMed, Embase, CENTRAL (Cochrane Central Register of Controlled Trials), and ClinicalTrials.gov from inception through July 2024 to identify primary interventional studies among pediatric patients with FH. Meta-analyses were performed if appropriate. Statistics were analyzed using Review Manager version 5.4 and Stata version 16.0. Results : Fourteen articles reporting nine unique studies were included. There were three randomized controlled trials (RCTs) assessing evolocumab or alirocumab involving a total of 320 pediatric patients, one cross-over trial and five single-arm or observational studies.", "population": "not extracted", "quote": "Pooled results showed significant efficacy of evolocumab/alirocumab in reducing low-density lipoprotein cholesterol (LDL-C) (weighted mean difference [WMD]: -37.92%, 95% confidence interval [CI]: -43.06% to -32.78%; I 2 = 0.0%, p = 0.60), apolipoprotein B (WMD: -33.67%, 95% CI: -38.12% to -29.22%; I 2 = 0.0%, p = 0.71), and also lipoprotein(a) (WMD: -16.94%, 95% CI: -26.20% to -7.69%; I 2 = 0.0%, p = 0.71) among pediatric patients with FH. Patients with concentrations of LDL-C of more than 190 mg/dL) and no FH mutations had a six times higher risk of coronary artery disease compared with people with concentrations of LDL-C of less than 130 mg/dL and no mutations.", "source_id": "source_11", "study": "Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.3390/medicina60101646"}, {"cited_as": "Choi 2023", "directness": "review", "doi": "10.1155/2023/7362551", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Alirocumab and evolocumab, as protein convertase subtilisin kexin type 9 (PCSK9) inhibitors, have been reported to reduce cardiovascular risk. This meta-analysis is aimed at updating the safety data of PCSK9 inhibitors. METHODS: We assessed the relative risk for all treatment-related adverse events, serious adverse events, diabetes-related adverse events, and neurocognitive and neurologic adverse events with PCSK9 inhibitors compared to controls (placebo or ezetimibe). In addition, we conducted a meta-analysis to quantitatively integrate and estimate the adverse event rates in long-term studies. RESULTS: There were no significant differences between PCSK9 inhibitors and controls in the relative risk analysis. In a subgroup analysis of each PCSK9 inhibitor, alirocumab treatment significantly reduced the risk of serious adverse events compared to control treatment (risk ratio (RR) = 0.937; 95% confidence interval (CI), 0.896-0.980), but no significant difference was observed with evolocumab treatment (RR = 1.003; 95% CI, 0.963-1.054).", "population": "not extracted", "quote": "In a subgroup analysis of each PCSK9 inhibitor, alirocumab treatment significantly reduced the risk of serious adverse events compared to control treatment (risk ratio (RR) = 0.937; 95% confidence interval (CI), 0.896-0.980), but no significant difference was observed with evolocumab treatment (RR = 1.003; 95% CI, 0.963-1.054). Moreover, alirocumab treatment afforded a significant reduction in the risk of diabetes-related adverse events compared to control treatment (RR = 0.9137; 95% CI, 0.845-0.987).", "source_id": "source_12", "study": "An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors", "support_kind": "bundle_reference", "url": "https://doi.org/10.1155/2023/7362551"}, {"cited_as": "Wang 2022a", "directness": "review", "doi": "10.1186/s12933-022-01542-4", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: The Food and Drug Administration has approved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors for the treatment of dyslipidemia. However, evidence of the optimal PCSK9 agents targeting PCSK9 for secondary prevention in patients with high-risk of cardiovascular events is lacking. Therefore, this study was conducted to evaluate the benefit and safety of different types of PCSK9 inhibitors. METHODS: Several databases including Cochrane Central, Ovid Medline, and Ovid Embase were searched from inception until March 30, 2022 without language restriction. Randomized controlled trials (RCTs) comparing administration of PCSK9 inhibitors with placebo or ezetimibe for secondary prevention of cardiovascular events in patients with statin-background therapy were identified. The primary efficacy outcome was all-cause mortality. The primary safety outcome was serious adverse events. RESULTS: Overall, nine trials totaling 54,311 patients were identified. Three types of PCSK9 inhibitors were evaluated. The use of alirocumab was associated with reductions in all-cause mortality compared with control (RR 0.83, 95% CrI 0.72-0.95).", "population": "not extracted", "quote": "The use of alirocumab was associated with reductions in all-cause mortality compared with control (RR 0.83, 95% CrI 0.72-0.95). Moreover, evolocumab was associated with increased all-cause mortality compared with alirocumab (RR 1.26, 95% CrI 1.04-1.52).", "source_id": "source_13", "study": "PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.1186/s12933-022-01542-4"}, {"cited_as": "Masson 2026", "directness": "review", "doi": "10.1007/s12325-025-03418-x", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "INTRODUCTION: Pharmacological inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is a well-established strategy for achieving substantial reductions in low-density lipoprotein cholesterol (LDL-C). Recently, novel oral PCSK9 inhibitors have emerged, providing new evidence regarding their lipid-lowering efficacy and safety. METHODS: This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. Randomized clinical trials evaluating oral PCSK9 inhibitors and reporting percentage changes in lipid parameters and/or adverse events were included. A qualitative synthesis was performed for all studies meeting predefined eligibility criteria, followed by a quantitative synthesis of studies with sufficient data for statistical pooling. RESULTS: Seven randomized clinical trials were included in the qualitative analysis, of which four were eligible for meta-analysis. Five oral PCSK9 inhibitors were identified. Three agents (MK-0616, AZD0780, and NNC0385-0434) contributed to the quantitative analysis, while two (DC371739 and CVI-LM001) were assessed descriptively.", "population": "not extracted", "quote": "Compared with placebo, oral PCSK9 inhibitors significantly reduced LDL-C [mean difference (MD) - 55.7; 95% confidence interval (CI) - 59.3 to - 52.1; I 2 = 14%)] and apolipoprotein B (MD - 46.9; 95% CI - 54.6 to - 39.2; I 2 = 72.9%). They also lowered non-high-density lipoprotein cholestero (MD - 49.4; 95% CI - 57.4 to - 41.5; I 2 = 50.3%), triglycerides (MD - 13.2; 95% CI - 21.4 to - 5.0; I 2 = 0%), and lipoprotein(a) (MD - 24.9; 95% CI - 34.9 to - 15.0; I 2 = 77.6%).", "source_id": "source_14", "study": "Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.1007/s12325-025-03418-x"}, {"cited_as": "Chen 2026", "directness": "direct", "doi": "10.1136/bmjopen-2025-112947", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "The background evidence for pcsk9 inhibitors effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Karatasakis 2017 [bundle:31], Chen 2026 [bundle:15], Gong 2025 [bundle:26] are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.", "excerpt": "INTRODUCTION: The 'strike early and strike strong' lipid-lowering strategy emphasises rapid reduction of low-density lipoprotein cholesterol (LDL-C) in patients with acute coronary syndrome (ACS). Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are increasingly used alongside statins to achieve guideline-recommended LDL-C targets after ACS. However, despite substantial LDL-C reductions with early PCSK9i initiation, their effects on non-culprit coronary atherosclerotic plaques remain unclear. This study aims to assess the impact of early intensive LDL-C lowering with PCSK9i added to moderate-intensity statin therapy on optical coherence tomography (OCT)-derived plaque characteristics in non-culprit coronary lesions in patients with ACS. METHODS AND ANALYSIS: In this prospective, multicentre, open-label trial, 212 patients with ACS will be randomised 1:1 to an early intensified lipid-lowering strategy (PCSK9i added to moderate-intensity statin) or guideline-directed medical therapy for 6 months. Serial OCT imaging of non-culprit coronary arteries with 20-70% stenosis will be performed at baseline and 6 months.", "population": "not extracted", "quote": "The primary endpoint will be analysed using analysis of covariance, adjusting for treatment group, baseline LDL-C stratification (≥1.8 vs <1.8 mmol/L), and baseline minimum FCT. 1 Because non-culprit plaques are prone to rupture and thrombosis, patients with ACS remain at elevated risk of recurrent cardiovascular events, especially during the first 30 to 90 days after discharge.", "source_id": "source_15", "study": "PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial", "support_kind": "bundle_reference", "url": "https://doi.org/10.1136/bmjopen-2025-112947"}, {"cited_as": "Jiang 2025", "directness": "review", "doi": "10.3389/fcvm.2024.1415668", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: The objective of this study is to assess the relative efficacy of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as alirocumab, evolocumab, and inclisiran, in conjunction with potent statins like atorvastatin and rosuvastatin, in patients presenting with hyperlipidemia or heightened cardiovascular risk attributable to elevated low-density lipoprotein cholesterol (LDL-C). METHODS: A systematic search was conducted across databases including PubMed, Embase, and the Cochrane Library to explore lipid-lowering therapies in hyperlipidemia from their inception to 7 November 2023. A network meta-analysis (NMA) was conducted via Stata 17 software, with two authors independently conducting the search, screening, and data abstraction. RESULTS: A total of 68 clinical studies involving 21,288 patients with hyperlipidemia were incorporated into the NMA. PSCK9 inhibitors and potent statins significantly reduced LDL-C levels from baseline vs. placebo regardless of background therapy. Regarding the efficacy of lipid reduction, four principal medications were evaluated: evolocumab and atorvastatin [mean standard deviation (MD) -3.41, 95% CI -4.81 to -2.", "population": "not extracted", "quote": "Meanwhile, compared with placebo, evolocumab (MD -1.89, 95% CI -2.27 to -1.50), alirocumab (MD -1.83, 95% CI -2.09 to -1.57), rosuvastatin (MD -1.93, 95% CI -2.30 to -1.56), inclisiran (MD -1.68, 95% CI -2.10 to -1.27), and atorvastatin (MD -1.68, 95% CI -2.04 to -1.31) could also play a role in the treatment of LDL-C reduction. Moreover, the incidence of adverse events (AEs) was similar to that observed in the control group, which included both placebo and potent statin groups, with no significant differences identified in our study ( P > 0.05).", "source_id": "source_16", "study": "Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.3389/fcvm.2024.1415668"}, {"cited_as": "Li 2024", "directness": "review", "doi": "10.3389/fcvm.2024.1375040", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD), a leading cause of global fatalities, has inconsistent findings regarding the impact of muscle symptoms despite promising clinical trials involving PCSK9 inhibitors (PCSK9i) and siRNA as potential therapeutic options. METHODS: The databases EMBASE, PubMed, Web of Science, Cochrane, and ClinicalTrials.gov were thoroughly searched without any restrictions on language. Review Manager 5.3 software was utilized to calculate relative risks with 95% confidence intervals (CIs) for dichotomous data and mean differences or standardized mean differences with 95%CIs for continuous data. To evaluate publication bias, Egger's test was employed using Stata/SE software. RESULTS: This analysis included 26 studies comprising 28 randomized controlled trials (RCTs) involving a total of 100,193 patients, and 4 different lipid-lowering therapy combinations. For events with creatine kinase >3ULN, evolocumab and alirocumab demonstrated significant advantages compared to inclisiran. Evolocumab showed the best results in terms of both new muscle symptom events and creatine kinase >3ULN.", "population": "not extracted", "quote": "Review Manager 5.3 software was utilized to calculate relative risks with 95% confidence intervals (CIs) for dichotomous data and mean differences or standardized mean differences with 95%CIs for continuous data. According to the 2018 AHA/ACC guideline and the 2017 National Lipid Association update, PCSK9 inhibitors were recommended for patients with LDL-C levels ≥70 mg/dl or non-high-density lipoprotein cholesterol (non-HDL-C) ≥100 mg/dl after maximally tolerated LDL-lowering therapies ( 8 , 9 ).", "source_id": "source_17", "study": "PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a systematic review and network meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.3389/fcvm.2024.1375040"}, {"cited_as": "Bosco 2025", "directness": "indirect", "doi": "10.1186/s12967-025-07432-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Familial hypercholesterolemia (FH) is characterized by lifelong elevated LDL-C levels and increased cardiovascular risk. PCSK9 inhibitors (PCSK9i) reduce LDL-C and Lp(a), however, the effect of dual lipid reduction on mechanical vascular function remains unclear. The aim of this study was to evaluate the efficacy of PCSK9i in reducing LDL-C and Lp(a) and to assess the relationship between the dual lipid reduction and the mechanical vascular profile improvement in FH subjects. METHODS: This prospective observational study included 301 genetically confirmed FH subjects treated with PCSK9i added to high-intensity statins and ezetimibe. Biochemical and PWV measurements were performed at baseline and after six months. Subjects were stratified into four groups based on median values of ΔLDL-C and ΔLp(a). RESULTS: After six months of add-on PCSK9i, 44.9% of FH subjects achieved their LDL-C targets. Reductions were observed in LDL-C (− 49.8%, p < 0.001), Lp(a) (− 21.4%, p < 0.001), and PWV (Δ − 22.7%, p < 0.001). PWV improvement increased across groups with greater lipid reductions (p for trend < 0.01); Group 3 and Group 4 exhibited a similar mechanical vascular benefit.", "population": "not extracted", "quote": "Evidence from phase III trials with PCSK9 monoclonal antibodies (PCSK9-mAb) such as alirocumab and evolocumab has demonstrated that an LDL-C reduction of 50-60% is associated with a lower rate of cardiovascular events [ 6 , 7 ]. FOURIER Outcomes and ODYSSEY OUTCOMES trials showed an Lp(a) reduction of 20-25% with PCSK9-mAb that was associated with a lower incidence of cardiovascular events [ 17 , 18 ].", "source_id": "source_18", "study": "Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects", "support_kind": "bundle_reference", "url": "https://doi.org/10.1186/s12967-025-07432-z"}, {"cited_as": "Chen 2024", "directness": "review", "doi": "10.1186/s12891-024-07674-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent an effective strategy for reducing cardiovascular disease risk. Yet, PCSK9's impact on osteoporosis remains unclear. Hence, we employed Mendelian randomization (MR) analysis for examining PCSK9 inhibitor effects on osteoporosis. METHODS: Single nucleotide polymorphisms (SNPs) for 3-hydroxy-3-methylglutaryl cofactor A reductase (HMGCR) and PCSK9 were gathered from available online databases for European pedigrees. Four osteoporosis-related genome-wide association studies (GWAS) data served as the main outcomes, and coronary artery disease (CAD) as a positive control for drug-targeted MR analyses. The results of MR analyses examined by sensitivity analyses were incorporated into a meta-analysis for examining causality between PCSK9 and HMGCR inhibitors and osteoporosis. RESULTS: The meta-analysis involving a total of 1,263,102 subjects, showed that PCSK9 inhibitors can increase osteoporosis risk (P < 0.05, I 2 , 39%). However, HMGCR inhibitors are not associated with osteoporosis risk.", "population": "not extracted", "quote": "The meta-analysis involving a total of 1,263,102 subjects, showed that PCSK9 inhibitors can increase osteoporosis risk ( P < 0.05, I 2 , 39%). It has been shown that these medications may considerably lower mortality in CAD patients by up to 30%.", "source_id": "source_19", "study": "PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.1186/s12891-024-07674-w"}, {"cited_as": "Zhang 2025", "directness": "review", "doi": "10.1371/journal.pone.0329676", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs used for the treatment of dyslipidemia. PCSK9 inhibitors have been shown to remarkably reduce cardiovascular events in patients at high risk, but data on their impact on sudden cardiac death (SCD) and ventricular arrhythmias are limited. This study aimed to evaluate whether PCSK9 inhibitor therapy reduces the risk of SCD and ventricular arrhythmias. METHODS: PubMed and Embase were searched up to September 1, 2024 and combined with data from ClinicalTrials.gov. Randomized controlled trials of PCSK9 inhibitors with ≥ 450 patients and follow-up of ≥ 48 weeks were considered for inclusion. Primary outcomes were the incidence of SCD and ventricular arrhythmias. We used a random-effects model to synthesize the data, calculating risk ratio (RR) and 95% confidence intervals (CI). Heterogeneity between studies was assessed with I² statistics. Risk of bias was assessed using the Cochrane risk of bias tool. RESULTS: A total of 12 articles with 16 trials involving 90,764 patients were included. The follow-up duration ranged from 48 weeks to 3.4 years.", "population": "not extracted", "quote": "Randomized controlled trials of PCSK9 inhibitors with ≥ 450 patients and follow-up of ≥ 48 weeks were considered for inclusion. PCSK9 inhibitor therapy did not significantly reduce the risk of SCD (RR 0.83, 95% CI 0.54-1.28; P = 0.40; I 2 = 0%), ventricular arrhythmias (RR 0.81, 95% CI 0.60-1.09; P = 0.17; I 2 = 0%), and cardiac arrest (RR 1.20, 95% CI 0.61-2.33; P = 0.60; I 2 = 0%).", "source_id": "source_20", "study": "Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A meta-analysis of randomized controlled trials", "support_kind": "bundle_reference", "url": "https://doi.org/10.1371/journal.pone.0329676"}, {"cited_as": "Barbati 2024", "directness": "indirect", "doi": "10.1371/journal.pone.0309470", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Low-Density Lipoprotein (LDL) cholesterol is one of the main target for cardiovascular (CV) prevention and therapy. In the last years, Proprotein Convertase Subtilisin-Kexin type 9 inhibitors (PCSK9-i) has emerged as a key therapeutic target to lower LDL and were introduced for prevention of CV events. Recently (June 2022) the Italian Medicines Agency (AIFA) modified the eligibility criteria for the use of PCSK9-i. We designed an observational study to estimate the prevalence of eligible subjects and evaluate the effectiveness of PCSK9-i applying a Target Trial Emulation (TTE) approach based on Electronic Health Records (EHR). Subjects meeting the eligibility criteria were identified from July 2017 (when PCSK9-i became available) to December 2020. Outcomes were all-cause death and the first hospitalization. Among eligible subjects, we identified those treated at date of the first prescription. Inverse Probability of Treatment Weights (IPTW) were estimated including demographic and clinical covariates, history of treatment with statins and the month/year eligibility date.", "population": "not extracted", "quote": "Inhibition of PCSK9 by the use of monoclonal antibodies has been demonstrated to significantly reduce LDL values (Low-Density Lipoprotein) by 50-70%, regardless of the therapeutic background in which it is implemented (monotherapy or in combination with the standard Lipid-Lowering Therapy, LLT) [ 6 ]. Moreover, in addition to the Average Treatment Effect (ATE), the Conditional Average Treatment Effect (CATE) [ 17 ] was estimated to evaluate the absolute reduction of the risk of events in the mutually exclusive subgroups derived from the eligibility criteria as follows: Documented AtheroSclerotic CardioVascular event (ASCVD) as the only eligibility criteria (“ASCVD”) Diabetes with Target Organ Damage (TOD) or at least a Risk Factor (RF) among smoking or hypertension in absence of documented ASCVD (“Diabetes TOD/RF”) Diabetes with TOD or at least a Risk Factor (RF) in presence of documente", "source_id": "source_21", "study": "Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records", "support_kind": "bundle_reference", "url": "https://doi.org/10.1371/journal.pone.0309470"}, {"cited_as": "Seijas-Amigo 2023", "directness": "indirect", "doi": "10.1007/s40256-023-00604-6", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "INTRODUCTION: The cognitive safety of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) has been established in clinical trials, but not yet in real-world observational studies. We assessed the cognitive function in patients initiating PCSK9i, and differences in cognitive function domains, to analyze subgroups by the low-density lipoprotein cholesterol (LDL-C) achieved, and differences between alirocumab and evolocumab. METHODS: This has a multicenter, quasi-experimental design carried out in 12 Spanish hospitals from May 2020 to February 2023. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA). RESULTS: Among 158 patients followed for a median of 99 weeks, 52% were taking evolocumab and 48% alirocumab; the mean change from baseline in MoCA score at follow-up was + 0.28 [95% CI (- 0.17 to 0.73; p = 0.216)]. There were no significant differences in the secondary endpoints-the visuospatial/executive domain + 0.04 (p = 0.651), naming domain - 0.01 (p = 0.671), attention/memory domain + 0.01 (p = 0.945); language domain - 0.10 (p = 0.145), abstraction domain + 0.03 (p = 0.624), and orientation domain - 0.05 (p = 0.", "population": "not extracted", "quote": "Alirocumab and evolocumab are the first class of PCSK9i that demonstrated in randomized clinical trials the ability to reduce the LDL-C levels by about 60% [ 9 , 10 ]. Recently, in FOURIER-OLE [ 19 ], an open-label extension study with evolocumab and with a follow-up of 8.4 years, neurocognitive events with evolocumab in the long term did not exceed those reported for placebo-treated patients.", "source_id": "source_22", "study": "Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study", "support_kind": "bundle_reference", "url": "https://doi.org/10.1007/s40256-023-00604-6"}, {"cited_as": "Wang 2022b", "directness": "review", "doi": "10.3389/fcvm.2022.1016802", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: The efficacy of anti-proprotein convertase subtilisin/Kexin type 9 (PCSK9) monoclonal antibodies in patients with atherosclerotic cardiovascular disease (ASCVD) remains unclear. Therefore, this study aims to assess the effect of PCSK9 inhibitors (alirocumab and evolocumab) on ASCVD patients considering the number needed to treat (NNT). METHODS: We reviewed randomized controlled trials (RCTs) which compared the effects of alirocumab or evolocumab and placebo or standards of care. All articles were published in English up to May 2022. Using random effect models, we estimated risk ratios (RRs), NNT, and 95% confidence intervals (CI). RESULTS: We incorporated 12 RCTs with 53 486 patients total, of which 27 674 received PCSK9 inhibitors and 25 812 received placebos. The mean follow-up duration was 1.56 years. The effect of PCSK9 inhibitors on major adverse cardiovascular events (MACE) was statistically significant, and the corresponding mean NNT was 36. Alirocumab reduced the risk of MACE, stroke, and coronary revascularization; the corresponding mean NNT were 37, 319, and 107, respectively.", "population": "not extracted", "quote": "This study suggests that preventing one patient from MACE needed to treat 36 patients with ASCVD with PCSK9 inhibitors for 1.56 years. The effect of PCSK9 inhibitors on MACE was statistically significant (RR 0.83, 95% CI 0.79-0.87) ( Supplementary Figure 3 ), and the corresponding NNT was 36 (NNTB 29 to NNTB 47).", "source_id": "source_23", "study": "Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat", "support_kind": "bundle_reference", "url": "https://doi.org/10.3389/fcvm.2022.1016802"}, {"cited_as": "Akhtar 2025", "directness": "indirect", "doi": "10.1038/s41598-025-22916-0", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "We looked to establish if Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor therapy can be safely initiated in heart transplant recipients and effectively reduce target low density lipoprotein (LDL). This prospective audit reviewed heart transplant recipients between 1st June 2019 and 1st November 2022 at Harefield Hospital in London. At baseline all patients must have attempted statin and ezetimibe therapy. All patients who remained with an LDL > 3.5 with very high cardiovascular risk or LDL > 4.0mmol/L with high risk were initiated on alirocumab injection every 2 weeks. Monitoring including biochemical analysis including immunotherapy levels, troponin, brain natriuretic peptides, electrocardiograph and echocardiogram. PCKS9i therapy was tolerated in 9/11 patients with 2 stopping treatment, one due to nausea & vomiting and one due to elevation in creatinine kinase. No adverse effects related to the heart transplant were detected and no significant change in creatinine kinase, liver function or left ventricular ejection fraction were seen. A significant reduction in LDL, total cholesterol, triglycerides was seen with LDL cholesterol reduction of 55% from 4.14 ± 0.", "population": "not extracted", "quote": "Estimated treatment effects constant over time expects to reduce LDL by about 2.19 to 2.77 mmol/L with 95% probability. Total cholesterol is likely to be lowered by 2.22 to 2.91 mmol/L and triglycerides by 0.42 to1.6 mmol/L with the same probability.", "source_id": "source_24", "study": "PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre observational study", "support_kind": "bundle_reference", "url": "https://doi.org/10.1038/s41598-025-22916-0"}, {"cited_as": "Yu 2026", "directness": "indirect", "doi": "10.1161/JAHA.125.047923", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Combining PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors with statins significantly lowers low-density lipoprotein cholesterol and reduces cardiovascular events in patients with coronary heart disease versus statins alone. However, it remains unclear which monotherapy offers greater cardiovascular benefit. METHODS: This prospective non-randomized real-world observational cohort study enrolled coronary heart disease inpatients from July 2020 to March 2024. Patients received either alirocumab (75 mg/2 weeks) or statins (atorvastatin 20 mg/day or rosuvastatin 10 mg/day). The primary outcome was a composite of cardiovascular death, myocardial infarction, stroke, heart failure hospitalization, or coronary revascularization. Cox proportional hazards models and restricted mean survival time analyses were used. RESULTS: Among 1165 analyzed patients, 215 received PCSK9 inhibitors and 950 received statins. After 1 month, low-density lipoprotein cholesterol reduction was greater in the PCSK9 inhibitor group (from 2.57 to 0.75 mmol/L) than in the statin group (from 2.29 to 1.40 mmol/L; P <0.001). However, this difference was not significant at 12 months (1.", "population": "not extracted", "quote": "After 1 month, low‐density lipoprotein cholesterol reduction was greater in the PCSK9 inhibitor group (from 2.57 to 0.75 mmol/L) than in the statin group (from 2.29 to 1.40 mmol/L; P <0.001). Hypertension was defined as systolic blood pressure of ≥140 mm Hg and/or diastolic blood pressure of ≥90 mm Hg or current use of antihypertensive medication.", "source_id": "source_25", "study": "Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment", "support_kind": "bundle_reference", "url": "https://doi.org/10.1161/JAHA.125.047923"}, {"cited_as": "Gong 2025", "directness": "direct", "doi": "10.1186/s13063-024-08709-2", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "The background evidence for pcsk9 inhibitors effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Karatasakis 2017 [bundle:31], Chen 2026 [bundle:15], Gong 2025 [bundle:26] are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.", "excerpt": "BACKGROUND: Early neurological deterioration (END) is a critical determinant influencing the short-term prognosis of acute ischemic stroke (AIS) patients and is associated with increased mortality rates among hospitalized individuals. AIS frequently coexists with coronary heart disease (CHD), complicating treatment and leading to more severe symptoms and worse outcomes. Shared risk factors between CHD and AIS, especially elevated low-density lipoprotein cholesterol (LDL-C), contribute to atherosclerosis and inflammation, which worsen brain tissue damage. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer a promising treatment option. They effectively lower LDL-C levels and may help reduce END in AIS patients with CHD. This study aims to evaluate how effective PCSK9 inhibitors are in reducing END among this high-risk group and to provide new insights for treatment strategies. METHODS: This is a prospective, randomized, parallel-group, blinded-endpoint, single-center clinical study.", "population": "not extracted", "quote": "3.Inability to control severe hypertension (systolic blood pressure persistently ≥180 mmHg or diastolic blood pressure ≥110 mmHg after active treatment), severe infections (meeting criteria such as elevated body temperature ≥38°C, signs of shock, infection-related consciousness impairment, respiratory failure, and blood gas analysis PO 2 <60 mmH 2 O), or abnormal liver function (ALT > 100 IU/L or AST > 80 IU/L), renal dysfunction (glomerular filtration rate < 30 ml/min), or patients with bleeding tendencies in the blood system (platelets < 60×10 9 /L or APTT > 60 seconds or INR > 3). Secondary objectives include evaluating changes in daily living abilities, recurrence rates of cardiovascular and cerebrovascular events within 90 days, alterations in blood biochemical indices/markers, and variations in inflammatory factors between the two patient groups after treatment.", "source_id": "source_26", "study": "Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of coronary heart disease: a study protocol for a randomized controlled trial in Dalian, China", "support_kind": "bundle_reference", "url": "https://doi.org/10.1186/s13063-024-08709-2"}, {"cited_as": "Ray 2025", "directness": "review", "doi": "10.2174/011573403X345749250122092324", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "INTRODUCTION: Reducing the risk of atherosclerotic cardiovascular disease is the aim of lipid-lowering therapy (ASCVD). It is commonly acknowledged that low-density lipoprotein (LDL) is a major cause of ASCVD. Several online databases and search engines, such as Pub- Med and the Cochrane Library, were used to conduct a thorough search. METHODS: This study included RCTs assessing the effect of PCSK9 inhibitors on cardiovascular events. The RevMan 5.4 software was used to conduct the meta-analysis. This analysis included nine RCTs in total. RESULTS: Meta-analysis of the included studies showed that the levels of total cholesterol, LDL, and triglycerides were reduced after the use of PCSK9 inhibitors, and HDL levels were increased, which is good cholesterol. Most adverse cardiac events (MACE) were reduced after the use of PCSK9 inhibitors. CONCLUSION: In conclusion, ezetimibe, a PCSK9 inhibitor added to statin therapy, further reduces MACE risk without affecting all-cause mortality, even though statins already significantly reduce major adverse cardiovascular events (MACE) and mortality.", "population": "not extracted", "quote": "Methods: Publications in the English language that meet stress-related adaptation associated with an increased risk for cardiovascular disease guidelines, published within the past 5 years. Significant reductions in LDL-C were found with PCSK9 inhibitors compared with controls, with evolocumab and alirocumab showing LDL-C reductions of up o 72.9%.", "source_id": "source_27", "study": "The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis", "support_kind": "bundle_reference", "url": "https://doi.org/10.2174/011573403X345749250122092324"}, {"cited_as": "Theodorou 2025", "directness": "indirect", "doi": "10.1111/ene.70175", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND AND OBJECTIVES: Limited data exist on the efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and inclisiran among patients with neuromuscular disorders and statin-induced myotoxicity and/or hepatotoxicity. We assessed the safety and efficacy of PCSK9 inhibitors and inclisiran in this specific patient subgroup. METHODS: We conducted an observational cohort study evaluating patients with available clinical and laboratory data prior to and at prespecified time points following treatment initiation with PCSK9 inhibitors or inclisiran. RESULTS: Eleven patients with neuromuscular disorders and statin intolerance were included in this study. Median follow-up time after PCSK9 inhibitor or inclisiran initiation was 14 (9-17) months. PCSK9 inhibitors or inclisiran use led to a significant decrease in mean low-density lipoprotein cholesterol levels. Moreover, all patients tolerated these lipid-lowering agents without exacerbation of their underlying myositis, myopathy, neuromuscular junction disorder, and without presenting any adverse event or relapse of myotoxicity and/or hepatotoxicity.", "population": "not extracted", "quote": "PCSK9 inhibitors and inclisiran have been studied in patients with homozygous or heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease (ASCVD), and ASCVD risk equivalent (a high‐risk primary prevention cohort comprising individuals with type 2 diabetes mellitus, familial hypercholesterolemia, or a 10‐year risk of a CV event ≥ 20% [by Framingham Risk Score or equivalent]). During the first 3 months, mean LDL concentrations were significantly reduced (from 170.5 ± 52.0 mg/dL to 96.7 ± 20.6 mg/dL; p ‐value < 0.001) compared to baseline levels and during the following months remained stable at target levels (Figure 1A ).", "source_id": "source_28", "study": "Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin Intolerance", "support_kind": "bundle_reference", "url": "https://doi.org/10.1111/ene.70175"}, {"cited_as": "Ariyanti 2026", "directness": "review", "doi": "10.1080/03007995.2026.2662127", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: The role of PCSK9 inhibitors in PAD remains uncertain, despite their established benefits in atherosclerotic cardiovascular disease. This meta-analysis aimed to evaluate their effects on cardiovascular, functional, limb, and survival outcomes in PAD. METHODS: We systematically searched PubMed, Scopus, and ClinicalTrials.gov through August 2025 for RCTs and cohort studies comparing PCSK9 inhibitors with placebo or standard therapy in PAD. Primary outcomes were MACE and major amputation. Data were analyzed using fixed- or random-effects models depending on heterogeneity. RESULTS: Six studies (five RCTs, one cohort) involving 4,563 patients were included. PCSK9 inhibitors significantly reduced MACE (HR 0.77; 95% CI: 0.65 to 0.92) and lowered LDL-C levels (MD -55.76 mg/dL; 95% CI: -63.19 to -48.34). Positive but non-significant trends were observed for major amputation (HR 0.35; 95% CI: 0.11 to 1.07), all-cause mortality (HR 0.58; 95% CI: 0.26 to 1.30), and walking performance (SMD 2.38; 95% CI: -1.97 to 6.73).", "population": "not extracted", "quote": "PCSK9 inhibitors significantly reduced MACE (HR 0.77; 95% CI: 0.65 to 0.92) and lowered LDL-C levels (MD -55.76 mg/dL; 95% CI: -63.19 to -48.34). Positive but non-significant trends were observed for major amputation (HR 0.35; 95% CI: 0.11 to 1.07), all-cause mortality (HR 0.58; 95% CI: 0.26 to 1.30), and walking performance (SMD 2.38; 95% CI: -1.97 to 6.73).", "source_id": "source_29", "study": "Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in peripheral artery disease-a systematic review and meta-analysis.", "support_kind": "bundle_reference", "url": "https://doi.org/10.1080/03007995.2026.2662127"}, {"cited_as": "Hu 2025", "directness": "review", "doi": "10.1097/mca.0000000000001464", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease due to its unique apo(a) component and its association with atherosclerosis and thrombogenesis. This meta-analysis was conducted to evaluate the effects of PCSK9 inhibitors on major adverse cardiac events (MACE) and Lp(a) levels in patients with coronary heart disease. METHODS: Randomized controlled trials (RCTs) were systematically searched in PubMed, the Cochrane Library, and other databases. Stata 15.1 software was used for data analysis, and a random- or fixed-effects model was selected based on inter-study heterogeneity. Egger's test was applied to detect publication bias. RESULTS: A total of 12 RCTs were included, involving 48 116 patients with a mean age of 62 years, comprising 65% males and diverse ethnic backgrounds. The results showed that compared with the control group, PCSK9 inhibitors significantly reduced low-density lipoprotein cholesterol (WMD = -1.24 mmol/L, 95% confidence interval (CI): -1.28 to -1.20), total cholesterol, triglycerides, and Lp(a) levels while increasing high-density lipoprotein cholesterol levels.", "population": "not extracted", "quote": "The results showed that compared with the control group, PCSK9 inhibitors significantly reduced low-density lipoprotein cholesterol (WMD = -1.24 mmol/L, 95% confidence interval (CI): -1.28 to -1.20), total cholesterol, triglycerides, and Lp(a) levels while increasing high-density lipoprotein cholesterol levels. For MACE, PCSK9 inhibitors significantly reduced the risk of nonfatal myocardial infarction, stroke, and coronary revascularization events (RR = 0.87, 95% CI: 0.84-0.89).", "source_id": "source_30", "study": "Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a meta-analysis.", "support_kind": "bundle_reference", "url": "https://doi.org/10.1097/mca.0000000000001464"}, {"cited_as": "Karatasakis 2017", "directness": "direct", "doi": "10.1161/JAHA.117.006910", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "The background evidence for pcsk9 inhibitors effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Karatasakis 2017 [bundle:31], Chen 2026 [bundle:15], Gong 2025 [bundle:26] are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.", "excerpt": "BACKGROUND: We sought to examine the efficacy and safety of 2 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors: alirocumab and evolocumab. METHODS AND RESULTS: We performed a systematic review and meta-analysis of randomized controlled trials comparing treatment with and without PCSK9 inhibitors; 35 randomized controlled trials comprising 45 539 patients (mean follow-up: 85.5 weeks) were included. Mean age was 61.0±2.8 years, and mean baseline low-density lipoprotein cholesterol was 106±22 mg/dL. Compared with no PCSK9 inhibitor therapy, treatment with a PCSK9 inhibitor was associated with a lower rate of myocardial infarction (2.3% versus 3.6%; odds ratio [OR]: 0.72 [95% confidence interval (CI), 0.64-0.81]; P <0.001), stroke (1.0% versus 1.4%; OR: 0.80 [95% CI, 0.67-0.96]; P =0.02), and coronary revascularization (4.2% versus 5.8%; OR: 0.78 [95% CI, 0.71-0.86]; P <0.001). Overall, no significant change was observed in all-cause mortality (OR: 0.71 [95% CI, 0.47-1.09]; P =0.12) or cardiovascular mortality (OR: 1.01 [95% CI, 0.85-1.19]; P =0.95).", "population": "not extracted", "quote": "We performed a systematic review and meta‐analysis of randomized controlled trials comparing treatment with and without PCSK9 inhibitors; 35 randomized controlled trials comprising 45 539 patients (mean follow‐up: 85.5 weeks) were included. Compared with no PCSK9 inhibitor therapy, treatment with a PCSK9 inhibitor was associated with a lower rate of myocardial infarction (2.3% versus 3.6%; odds ratio [OR]: 0.72 [95% confidence interval (CI), 0.64-0.81]; P <0.001), stroke (1.0% versus 1.4%; OR: 0.80 [95% CI, 0.67-0.96]; P =0.02), and coronary revascularization (4.2% versus 5.8%; OR: 0.78 [95% CI, 0.71-0.86]; P <0.001).", "source_id": "source_31", "study": "Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials", "support_kind": "bundle_reference", "url": "https://doi.org/10.1161/JAHA.117.006910"}, {"cited_as": "Kuhl 2019", "directness": "indirect", "doi": "10.1371/journal.pone.0210373", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Hypercholesterolaemia is common in patients after cardiac transplantation. Monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) reduce low-density lipoprotein (LDL) cholesterol levels and subsequently the risk of cardiovascular events in patients with dyslipidaemia. There are no published data on the effect of this medication class on cholesterol levels in patients after cardiac transplantation. METHODS: In this retrospective study we investigated patients who were treated with PCSK9 inhibitors either because of intolerance of statins or residual hypercholesterolaemia with evidence of cardiac allograft vasculopathy. We compared the data of patients prior to the start with these medications with their most recent dataset. RESULTS: Ten patients (nine men; mean age 58±6 years) underwent cardiac transplantation 8.3±4.5 (range 3-15) years ago. The treatment duration of Evolocumab or Alirocumab was on average 296±125 days and lead to a reduction of total Cholesterol (281±52 mg/dl to 197±36 mg/dl; p = 0.002) and LDL Cholesterol (170±22 mg/dl to 101±39 mg/dl; p = 0.001).", "population": "not extracted", "quote": "The effect of PCSK9 therapy differed between individual patients and ranged from a 26% increase to a 66% decrease of LDL ( Fig 1 ). Therapy with PCSK9 inhibitors resulted in an overall LDL cholesterol reduction of 40%.", "source_id": "source_32", "study": "Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation", "support_kind": "bundle_reference", "url": "https://doi.org/10.1371/journal.pone.0210373"}, {"cited_as": "Du 2019", "directness": "review", "doi": "10.1136/heartjnl-2019-314763", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: To evaluate the effects of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors on major adverse cardiovascular events (MACE). METHODS: Our systematic review included randomised controlled trials if they studied PCSK9 inhibitors in patients for primary and/or secondary prevention of cardiovascular diseases or with hypercholesterolaemia/hyperlipidaemia. Dichotomous variables from individual studies were pooled by relative risks (RR) and their 95% CIs using the random-effect model. Risk difference (RD) in the 10-year frame was also estimated using the pooled RR and the estimated baseline risk using the control group. Grading of Recommendation Assessment, Development and Evaluation was used to assess the quality of evidence. RESULTS: We included 54 trials with 97 910 patients in the analysis. Compared with controls, PCSK9 inhibitors significantly reduced the risk of MACE by 16% (RR, 0.84; 95% CI 0.79 to 0.89; RD: 47 fewer per 1000 vs 286 as the baseline risk; 95% CI 32 to 59 fewer), non-fatal myocardial infarction (MI) by 17% (RR, 0.83; 95% CI 0.74 to 0.93; RD, 35 fewer per 1000 vs 207 as the baseline; 95% CI 13 to 53 fewer) and any stroke by 25% (RR, 0.", "population": "not extracted", "quote": "Dichotomous variables from individual studies were pooled by relative risks (RR) and their 95% CIs using the random-effect model. Compared with controls, PCSK9 inhibitors significantly reduced the risk of MACE by 16% (RR, 0.84; 95% CI 0.79 to 0.89; RD: 47 fewer per 1000 vs 286 as the baseline risk; 95% CI 32 to 59 fewer), non-fatal myocardial infarction (MI) by 17% (RR, 0.83; 95% CI 0.74 to 0.93; RD, 35 fewer per 1000 vs 207 as the baseline; 95% CI 13 to 53 fewer) and any stroke by 25% (RR, 0.75; 95% CI 0.65 to 0.85; RD, 16 fewer per 1000 vs 61 as the baseline; 95% CI 9 to 21 fewer) with moderate quality evidence.", "source_id": "source_33", "study": "Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis.", "support_kind": "bundle_reference", "url": "https://doi.org/10.1136/heartjnl-2019-314763"}, {"cited_as": "Khan 2018", "directness": "review", "doi": "10.1177/2047487318766612", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Background The comparative effects of statins, ezetimibe with or without statins and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors remain unassessed. Design Bayesian network meta-analysis was conducted to compare treatment groups. Methods Thirty-nine randomized controlled trials were selected using MEDLINE, EMBASE, and CENTRAL (inception - September 2017). Results In network meta-analysis of 189,116 patients, PCSK9 inhibitors were ranked as the best treatment for prevention of major adverse cardiovascular events (Surface Under Cumulative Ranking Curve (SUCRA), 85%), myocardial infarction (SUCRA, 84%) and stroke (SUCRA, 80%). PCSK9 inhibitors reduced the risk of major adverse cardiovascular events compared with ezetimibe + statin (odds ratio (OR): 0.72; 95% credible interval (CrI), 0.55-0.95; Grading of Recommendation Assessment, Development and Evaluation (GRADE) criteria: moderate), statin (OR: 0.78; 95% CrI: 0.62-0.97; GRADE: moderate) and placebo (OR: 0.63; 95% CrI: 0.49-0.79; GRADE: high). The PCSK9 inhibitors were consistently superior to groups for major adverse cardiovascular event reduction in secondary prevention trials (SUCRA, 95%).", "population": "not extracted", "quote": "Results In network meta-analysis of 189,116 patients, PCSK9 inhibitors were ranked as the best treatment for prevention of major adverse cardiovascular events (Surface Under Cumulative Ranking Curve (SUCRA), 85%), myocardial infarction (SUCRA, 84%) and stroke (SUCRA, 80%). PCSK9 inhibitors reduced the risk of major adverse cardiovascular events compared with ezetimibe + statin (odds ratio (OR): 0.72; 95% credible interval (CrI), 0.55-0.95; Grading of Recommendation Assessment, Development and Evaluation (GRADE) criteria: moderate), statin (OR: 0.78; 95% CrI: 0.62-0.97; GRADE: moderate) and placebo (OR: 0.63; 95% CrI: 0.49-0.79; GRADE: high).", "source_id": "source_34", "study": "A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.", "support_kind": "bundle_reference", "url": "https://doi.org/10.1177/2047487318766612"}, {"cited_as": "Turgeon 2018", "directness": "review", "doi": "10.1016/j.cjca.2018.04.002", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are efficacious lipid-lowering agents, but more precise estimates of their effects on major adverse cardiovascular events (MACE), mortality, and safety are needed. We systematically reviewed and meta-analyzed randomized controlled trials with durations ≥ 6 months comparing MACE, mortality, and safety with PCSK9 inhibitors vs control. We searched CENTRAL, Embase, MedLine and the grey literature to November 7, 2018. From 2048 articles, we included 23 trials (n = 60,723). PCSK9 inhibitors reduced MACE (relative risk, 0.83; 95% confidence interval, 0.78-0.88), but did not clearly reduce mortality (relative risk, 0.93; 95% confidence interval, 0.85-1.02) or increase adverse events. In conclusion, PCSK9 inhibitors reduce nonfatal MACE, are well tolerated, but effects on mortality remain unclear.", "population": "not extracted", "quote": "We systematically reviewed and meta-analyzed randomized controlled trials with durations ≥ 6 months comparing MACE, mortality, and safety with PCSK9 inhibitors vs control. PCSK9 inhibitors reduced MACE (relative risk, 0.83; 95% confidence interval, 0.78-0.88), but did not clearly reduce mortality (relative risk, 0.93; 95% confidence interval, 0.85-1.02) or increase adverse events.", "source_id": "source_35", "study": "Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial.", "support_kind": "bundle_reference", "url": "https://doi.org/10.1016/j.cjca.2018.04.002"}, {"cited_as": "Schmidt 2017", "directness": "review", "doi": "10.1002/14651858.cd011748.pub2", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Despite the availability of effective drug therapies that reduce low-density lipoprotein (LDL)-cholesterol (LDL-C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL-C reduction may be warranted, especially for patients who are unresponsive to, or unable to take, existing LDL-C-reducing therapies. By inhibiting the proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme, monoclonal antibodies (PCSK9 inhibitors) may further reduce LDL-C, potentially reducing CVD risk as well. OBJECTIVES: Primary To quantify short-term (24 weeks), medium-term (one year), and long-term (five years) effects of PCSK9 inhibitors on lipid parameters and on the incidence of CVD. Secondary To quantify the safety of PCSK9 inhibitors, with specific focus on the incidence of type 2 diabetes, cognitive function, and cancer. Additionally, to determine if specific patient subgroups were more or less likely to benefit from the use of PCSK9 inhibitors. SEARCH METHODS: We identified studies by systematically searching the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and Web of Science.", "population": "not extracted", "quote": "Primary To quantify short-term (24 weeks), medium-term (one year), and long-term (five years) effects of PCSK9 inhibitors on lipid parameters and on the incidence of CVD. We compared PCSK9 inhibitors with placebo (thirteen RCTs), ezetimibe (two RCTs) or ezetimibe and statins (five RCTs).Compared with placebo, PCSK9 inhibitors decreased LDL-C by 53.86% (95% confidence interval (CI) 58.64 to 49.08; eight studies; 4782 participants; GRADE: moderate) at 24 weeks; compared with ezetimibe, PCSK9 inhibitors decreased LDL-C by 30.20% (95% CI 34.18 to 26.23; two studies; 823 participants; GRADE: moderate), and compared with ezetimibe and statins, PCSK9 inhibitors decreased LDL-C by 39.20% (95% CI 56.15 to 22.26; five studies; 5376 participants; GRADE: moderate).Compared with placebo, PCSK9 inhibitors decreased the risk of CVD events, with a risk difference (RD) of 0.91% (odds ratio (OR) of 0.86, ", "source_id": "source_36", "study": "PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.", "support_kind": "bundle_reference", "url": "https://doi.org/10.1002/14651858.cd011748.pub2"}], "claim": "Findings Map accounting note: each outcome-class n, direction count, directness count, and source roster is computed from the same source-level rows listed in the detailed table. Receipt-level direction is not a statement that the source abstracts lack directional statistics; it is the conservative coded polarity used for synthesis accounting. Outcome-class roster: Cardiometabolic n=14 (direction: negative=1; null=4; positive=6; unclear=3; directness: direct=1; indirect=3; review=10; sources: Ariyanti 2026 [bundle:29]; Cao 2025 [bundle:6]; Du 2019 [bundle:33]; Gong 2025 [bundle:26]; Hollstein 2021 [bundle:2]; Imran 2023 [bundle:3]; Khan 2018 [bundle:34]; Raone 2025 [bundle:9]; Ray 2025 [bundle:27]; Rehues 2023 [bundle:5]; Scicali 2021 [bundle:4]; Turgeon 2018 [bundle:35]; Wang 2022a [bundle:13]; Wang 2022b [bundle:23]); Contextual Adjacent Evidence n=9 (direction: null=1; positive=3; unclear=5; directness: direct=1; indirect=7; review=1; sources: Akhtar 2025 [bundle:24]; Barbati 2024 [bundle:21]; Bosco 2025 [bundle:18]; Chen 2026 [bundle:15]; Hosseini 2024 [bundle:1]; Jing 2025 [bundle:8]; Kuhl 2019 [bundle:32]; Seijas-Amigo 2023 [bundle:22]; Yu 2026 [bundle:25]); Safety and Comorbidity n=6 (direction: mixed=1; null=5; directness: indirect=1; review=5; sources: Jiang 2025 [bundle:16]; Liu 2024 [bundle:7]; Masson 2026 [bundle:14]; Song 2024 [bundle:10]; Theodorou 2025 [bundle:28]; Xiao 2024 [bundle:11]); Safety n=3 (direction: mixed=1; null=1; positive=1; directness: direct=1; review=2; sources: Choi 2023 [bundle:12]; Karatasakis 2017 [bundle:31]; Schmidt 2017 [bundle:36]); Longevity n=1 (direction: positive=1; directness: review=1; sources: Hu 2025 [bundle:30]); Mortality and Survival n=1 (direction: null=1; directness: review=1; sources: Zhang 2025 [bundle:20]); Muscle Function n=1 (direction: null=1; directness: review=1; sources: Li 2024 [bundle:17]); Skeletal, Fracture, and Bone n=1 (direction: mixed=1; directness: review=1; sources: Chen 2024 [bundle:19]).", "claim_id": "claim_28"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "Tension-accounting note: disagreement counts are claim-level. Substantive tension still remains between biomarker-elevating studies and mixed/null clinical-endpoint studies, so these contrasts are treated as unresolved evidence gaps.", "claim_id": "claim_29"}, {"candidate_sources": [{"cited_as": "Hosseini 2024", "comparator": "not extracted", "directness": "review", "doi": "10.1186/s12872-024-04057-w", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain. METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_1", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1186/s12872-024-04057-w", "year": 2024}, {"cited_as": "Hollstein 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. METHODS: In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. RESULTS: At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "LDL-C reduction was 7.1% greater in patients receiving statins than in those not receiving statins because of statin intolerance ( P < 0.0001). Overall, 47.1% of patients reported adverse events at week 68.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_2", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s40256-020-00411-3", "year": 2021}, {"cited_as": "Imran 2023", "comparator": "not extracted", "directness": "review", "doi": "10.1371/journal.pone.0295359", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear. OBJECTIVE: The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials. METHODS: Using Pubmed, Embase, Cochrane Library and clinicaltrials.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality.", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_3", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1371/journal.pone.0295359", "year": 2023}, {"cited_as": "Scicali 2021", "comparator": "not extracted", "directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05).", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Arterial hypertension was defined as brachial blood pressure (BP) ≥ 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the subjects were on antihypertensive therapy [ 23 ].", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_4", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1007/s00592-021-01703-z", "year": 2021}, {"cited_as": "Rehues 2023", "comparator": "not extracted", "directness": "indirect", "doi": "10.3390/ijms24032319", "effect": "not extracted", "endpoint": "not extracted", "evidence_span": "Substantive evidence synthesis: The manifest includes 36 retained sources, 3 direct-source row(s), and receipt-level directional coding across mixed=3, negative=1, null=13, positive=11, unclear=8. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Hosseini 2024 [bundle:1]: outcome=Contextual Adjacent Evidence; direction=positive; directness=review; tier=B1; result=Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute; finding=108 extracted claim(s); receipt-level direction is the coded finding; claims=108; Hollstein 2021 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; finding=representative statistic P < 0.0001; source-level statistic reported; claims=105; Imran 2023 [bundle:3]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; finding=representative statistic p<0.01; source-level statistic reported; claims=95; Karatasakis 2017 [bundle:31]: outcome=Safety; direction=mixed; directness=direct; tier=A1; result=Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; finding=representative statistic P <0.001; source-level statistic reported; claims=94; Rehues 2023 [bundle:5]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; finding=representative statistic p < 0.001; source-level statistic reported; claims=87; Cao 2025 [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B2; result=Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in; finding=representative statistic p < 0.001; source-level statistic reported; claims=82; Jing 2025 [bundle:8]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; finding=representative statistic P < 0.001; source-level statistic reported; claims=70; Raone 2025 [bundle:9]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease; finding=62 extracted claim(s); receipt-level direction is the coded finding; claims=62; Song 2024 [bundle:10]: outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1; result=Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; finding=representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; claims=59; Choi 2023 [bundle:12]: outcome=Safety; direction=positive; directness=review; tier=B2; result=An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; finding=43 extracted claim(s); receipt-level direction is the coded finding; claims=43; Wang 2022a [bundle:13]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis; finding=representative statistic p = 0.029; source-level statistic reported; claims=42; Bosco 2025 [bundle:18]: outcome=Biomarker/Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; finding=representative statistic p < 0.001; source-level statistic reported; claims=39; Kuhl 2019 [bundle:32]: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; finding=representative statistic p<0.001; source-level statistic reported; claims=39; Chen 2024 [bundle:19]: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2; result=PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; finding=representative statistic P < 0.05; source-level statistic reported; claims=32; Barbati 2024 [bundle:21]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records; finding=29 extracted claim(s); receipt-level direction is the coded finding; claims=29; Seijas-Amigo 2023 [bundle:22]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; finding=representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; claims=27; Akhtar 2025 [bundle:24]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre; finding=representative statistic p < 0.001; source-level statistic reported; claims=22; Yu 2026 [bundle:25]: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment; finding=representative statistic P <0.001; source-level statistic reported; claims=20; Khan 2018 [bundle:34]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Du 2019 [bundle:33]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and; finding=9 extracted claim(s); receipt-level direction is the coded finding; claims=9; Ariyanti 2026 [bundle:29]: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in; finding=3 extracted claim(s); receipt-level direction is the coded finding; claims=3; Turgeon 2018 [bundle:35]: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Hu 2025 [bundle:30]: outcome=Lipoprotein(a) / MACE in CHD; direction=positive; directness=review; tier=B1; result=Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Scicali 2021 [bundle:4]: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; finding=representative statistic p < 0.05; source-level statistic reported; claims=92; Liu 2024 [bundle:7]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; finding=71 extracted claim(s); receipt-level direction is the coded finding; claims=71; Xiao 2024 [bundle:11]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; finding=representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; claims=59; Li 2024 [bundle:17]: outcome=Muscle Function; direction=null; directness=review; tier=B2; result=PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; claims=40; Jiang 2025 [bundle:16]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; claims=40; Masson 2026 [bundle:14]: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2; result=Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Chen 2026 [bundle:15]: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study; finding=40 extracted claim(s); receipt-level direction is the coded finding; claims=40; Zhang 2025 [bundle:20]: outcome=Mortality and Survival; direction=null; directness=review; tier=B2; result=Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; claims=31; Wang 2022b [bundle:23]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on; finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded; claims=25; Gong 2025 [bundle:26]: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ray 2025 [bundle:27]: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Theodorou 2025 [bundle:28]: outcome=Safety and Comorbidity; direction=null; directness=indirect; tier=B2; result=Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin; finding=7 extracted claim(s); receipt-level direction is the coded finding; claims=7; Schmidt 2017 [bundle:36]: outcome=Safety; direction=null; directness=review; tier=B1; result=PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2. Contextual-adjacent subdomain map:  - adjacent clinical-context evidence: Hosseini 2024 [bundle:1], Jing 2025 [bundle:8], Chen 2026 [bundle:15], Bosco 2025 [bundle:18], Barbati 2024 [bundle:21], Seijas-Amigo 2023 [bundle:22], Akhtar 2025 [bundle:24] - treatment or intervention-response evidence: Kuhl 2019 [bundle:32], Yu 2026 [bundle:25]  These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.", "excerpt": "Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.", "intervention_or_exposure": "not extracted", "population": "not extracted", "quote": "Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001).", "risk_of_bias": "not appraised in public sidecar", "source_id": "source_5", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk", "support_kind": "candidate_source_row", "url": "https://doi.org/10.3390/ijms24032319", "year": 2023}], "citation_support": [], "claim": "| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |", "claim_id": "claim_30"}]}

metadata

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "bb8686c3-28f9-4609-95f1-70d7581bf992",
  "researka_submission_id": "e862b7cc-4ed5-452f-b1b9-7908f037ef87",
  "sidecar_name": "citation_traces.json",
  "sidecar_url": "https://api.researka.org/publications/bb8686c3-28f9-4609-95f1-70d7581bf992/sidecars/citation_traces.json"
}

view full chain →